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Introduction
Motivation of the present work
A disease is in a real sense a disordered physiology. Viruses, bacteria, mutations, etc. can trigger
pathological events. Our body reacts with molecular, cellular and systemic responses that are the
symptoms of disease. The ability to design drugs interfering with the progression of a disease comes
with: (i) the knowledge of pathological, cellular and molecular mechanisms involved in the disease;
(ii) the identiﬁcation of the macromolecules (i.e. possible drug targets) involved in pathological path-
ways, their 3D structures and their functions. Drugs are able to bind strongly (and selectively) to
target macromolecules involved in the pathological process, in order to interfere with their function.
The biological activity of drug molecules is dependent on the three-dimensional arrangement of func-
tional groups (the pharmacophores) which speciﬁcally bind to their target. Consequently, structural
information of the target protein is crucial in design of new drugs.
NMR spectroscopy and X-ray crystallography have provided the structures of hundreds of proteins
targeted in drug design [1, 2]. However, the gap between the number of proteins of known structures
and the number of sequences is increasing [3]. Determining the structure of membrane proteins
is especially diﬃcult. In the case experimental structural information is not available, molecular
modeling tools can be of great help. Particularly useful are comparative modeling approaches, that
enable to construct protein 3D structures from their amino acids sequences, based on the 3D data
of other similar proteins [4]. Since proteins are known to be in continuous motion between diﬀerent
conformations, it may be appropriate to combine such bioinformatics approaches with molecular
dynamics (MD) simulations, which allow to identify a spectrum of protein conformations. With MD
simulations important structural and functional features of the proteins, like ion binding or signiﬁcant
conformational changes can be observed at atomic detail.
Once drug target structures are known, molecular docking is used to locate drug candidates into
proteins binding pockets. This consists in accommodating each candidate drug molecule from a large
database in the binding pocket of the target, considered as rigid and without explicit treatment of
water. The procedure is computationaly eﬃcient. As binding of ligands may cause induced ﬁt it is often
necessary to study ligand-protein complexes by a more accurate and time-consuming technique. MD
simulations allow for hydration and conformational ﬂuctuations of the system. Using such simulations
key ligand-target interactions, the ligand binding paths and its binding aﬃnity can be elucidated.
Therefore, the use of bioinformatics, docking and molecular dynamics may be combined in powerful
way for structural prediction and drug design.
Following these approaches, in this thesis we focused on protein structural prediction and molecular
docking. Most often such approaches have been compared with experimental data, such as site-directed
mutagenesis as well as energetic or spectroscopic measurements. We have exploited the fact that in our
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School a large neurobiology Sector is present. Therefore, the above computational approaches have
been applied to systems of pharmacological relevance in neurobiological diseases. On one hand, (i) we
have focused on structural predictions of Ca2+-binding membrane proteins, for which at present, there
is no structural information available. On the other hand, (ii) we have addressed challenging docking
problems related to the prion protein, which is involved in transmissible spongiform encephalopathy
or prion disease.
The studied systems are of pharmacological and neurobiological interest due to their involvement
in severe degenerative diseases.
(i) Ca2+-gated ionic channels
Ca2+-gated channels, involved in the signaling in neurons and in the eye epithelium, are largely stud-
ied by neurobiologists. The malfunction of these channels causes diﬀerent diseases. Here we focused
on Ca2+- and voltage-gated potassium channel (BKCa) [5] as well as on Ca2+-gated Cl− channel
(bestrophin-1; Best1) [6]. To understand their functional properties, in particular Ca2+binding, and
consequently the pathological processes, structural information should be available. We have at-
tempted at modeling the structural determinants of BKCa and Best1 Ca2+-binding domains and to
get an insight into Ca2+ binding.
BKCa are ubiquitously present in our body [7, 8]. They are responsible to return excited neuronal
[9, 10] or muscular cells [11, 12] to the resting potential. The channels open upon an increase of
intracellular Ca2+ ions along with depolarization [5]. The result is eux of K+ ions from the cell
leading to a membrane hyperpolarization [13]. They are considered as putative targets for intervention
in cardiovascular, respiratory, and urological diseases, along with epilepsy and ischemic reperfusion
injury [7, 8]. Despite their function is well understood, the 3D structure and the details of Ca2+
binding, which leads to gating of the channel, are missing. To gain the structural information about
domains involved in Ca2+ binding we modeled two BKCa cytoplasmic domains: RCK1 (Regulator of
Conductance of K+) and calcium bowl.
Best1, a recently discovered family of Cl− channels, were suggested to be regulated by Ca2+ [6].
Mutations in Best1 leads to inherited macular dystrophy and consequently blindness known also as
Best disease [14, 15]. Many functionally relevant mutations are located in the so called Asp-rich
sequence at the C-terminal domain of Best1 [16, 6, 17, 18, 19]. Asp-rich domain shares signiﬁcant
sequence similarity with calcium bowl in BKCa[20, 21, 22]. Based on this analogy it has been suggested
that the Asp-rich domain can bind Ca2+ ions [23]. We constructed structural models of the Asp-rich
domain to understand its interactions with Ca2+ ions and to suggest mutational experiments, which
can give an important knowledge of Best1 physiological function as well as of the pathophysiology of
Best disease.
(ii) Prion protein
Prion diseases, or transmissible spongiform encephalopathies, are a group of fatal neurological diseases,
that aﬀect humans and animals [24]. Prion disease therapeutics can be targeted to the cellular form of
prion protein (PrPC), to its pathological form (PrPSc) or to the process of conversion between the two
of them. Interfering with the conversion of PrPC into PrPSc is a powerful strategy for pharmaceutical
intervention [25]. Stabilizing the structure of PrPC has the potential to remove the substrate for the
pathogenesis and is applicable regardless of the disease etiology [26].
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An excellent strategy to stabilize the PrPC is based on using small fragments of antibodies. Re-
cently, Fab D18 have been shown to permanently cure prion-infected cells by binding to the PrPC
[27, 28]. Unfortunately, Fab fragments cannot penetrate through the blood brain barrier what hampers
their potential use in prion disease therapy. A promising solution for this problem are single-chain
variable fragments (scFv) or mini-antibodies [29, 30, 31, 32]. Here, we investigated the anti-prion
eﬀects of D18scFv mini-antibody in collaboration with the experimental groups. We showed that
anti-prion D18scFv is able to reduce PrPSc in infected cell culture. Then, we constructed a structural
model of D18scFv. The PrPC was docked to it and the key molecular interactions between the two
proteins were deﬁned. The identiﬁed interactions allowed us to propose a mechanism explaining how
D18scFv reduced conversion and propagation of PrPC .
Another strategy to ﬁght prion diseases is to design ligands stabilizing the PrPC . Unfortunately,
however, in silico design of ligands targeting proteins undergoing ﬁbrillation in neurodegenerative
diseases, such as prion protein, is diﬃcult due to the lack of deep binding pockets in these proteins
and due to the paucity of 3D information of ligand-target complexes. Here, we established a compu-
tational approach that combines standard docking methods with molecular dynamics and free energy
simulations in explicit solvent to address this issue in the context of prion protein. The protocol pro-
vides detailed information about the binding process, binding aﬃnity and ligand-target interactions.
Our approach emerges as a novel tool for studying ligands binding to the proteins with ﬁbrillation
properties.
Outline of the thesis
Part I presents the computational tools used in this work: the comparative modeling and molecular
docking approaches along with molecular dynamics.
Part II presents structural predictions of Ca2+-binding domains in Ca2+-gated channels. A detailed
description of the structure and function of these proteins can be found in the following Chapters.
Chapter 4 focuses on human large conductance Ca2+- and voltage-gated potassium channel (hBKCa).
Bioinformatics approaches and MD simulations were used to construct models of two domains im-
portant for Ca2+ binding and channel gating, namely the Regulator of Conductance for K+ (RCK1)
and the so called calcium bowl. The relevance of these models for interpreting the available molecular
biology data is then discussed.
Chapter 5 deals with bestrophins, a recently discovered family of Cl− channels. Bestrophins
feature a well conserved Asp-rich tract in their C-terminal part, which is homologous to Ca2+-binding
motifs in calcium bowl of hBKCa. Based on these considerations, we constructed homology models
of human bestrophin-1 Asp-rich domain. MD simulations and free energy calculations were used
to identify Asp and Glu residues binding Ca2+ and to predict eﬀects of their mutations to Ala.
My work, performed in collaboration with C. Anselmi (SISSA/ISAS), was complemented by free
energy calculations carried out by F. Pietrucci (SISSA/ISAS ). Selected mutations were investigated
by electrophysiological experiments performed by Prof. A. Menini, J. Rievaj, F. W. Grillo, and A.
Boccaccio (SISSA/ISAS ). The model of Asp-rich domain was then validated against experimental
results.
Part III is devoted to the prion protein. In this Part, Chapter 6 presents in vitro studies of D18scFv
anti-prion eﬀects performed by groups of Prof. C. Zurzolo (Institut Pasteur, Paris, France), Prof.
G. Legname (SISSA/ISAS), L. Zentilin and M. Giacca (ICGEB, Trieste, Italy) and by Prof. S. B.
Prusiner (Institute for Neurodegenerative Diseases, University of California San Francisco, U.S.A.)
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and structural prediction of a complex between the small antibody fragment (D18scFv) and PrPC .
The complex was modeled using bioinformatics approaches. Initially, the D18scFv fragment alone was
modeled based on a similar antibody-fragment template and then docked with prion protein. Based
on this, interactions relevant for the recognition between the two proteins and for the mechanism of
action of D18scFv are discussed.
Chapter 7 describes a computational protocol for the design of ligands targeting cavity-less proteins,
like most proteins involved in neurodegenerative diseases. Molecular docking methods are combined
with MD simulations and free energy calculations using the metadynamics method [33, 34] to gain
insights in ligand binding to such proteins, in our case to prion protein. We focused on a compound
showing antiprion activity in vitro. Ligand-target interactions and ligand binding aﬃnity as emerged
by using our approach are compared with the available NMR data [35] and experimental constant of
dissociation [35]. In this work, also other two students and one postdoc were involved beside myself,
namely S. Bongarzone, G. Rossetti and X. Biarnes (SISSA/ISAS).
Finally, the conclusions are drawn in the last Chapter. The thesis closes with the List of publica-
tions and with the Acknowledgments.
Part I
Methods
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Chapter 1
Comparative modeling
Comparative modeling, known also as homology modeling, is a computational procedure for generating
3D models for proteins of unknown structures (targets) based on sequence similarity to proteins of
known structures (templates) [36]. It is based on the knowledge that protein structure is determined
by its amino acid sequence [37] and that the protein topology is better conserved across evolution
than the amino acid sequence. Therefore, the protein sequences that share detectable similarity with
a template, even if they are distantly related, will fold into similar structures [38, 39] (Figure 1.1).
Even when the models are approximate because of low sequence identity (SI) with the template,
diﬀerent biologically useful information can be extracted. The models constructed from the templates
with less than 30% of sequence identity might be used to reﬁne NMR structures, to ﬁnd binding/active
sites by 3D motif searching or to predict approximate biochemical function [36]. Models based on
30-50% of SI allow to predict locations and volumes of binding sites as well as to provide insight on
disease-linked mutations [36]. They are also useful in protein engineering. High quality models, based
on more than 50% of SI can be used for ligand-protein or protein-protein docking.
There are four main steps in constructing models (for review see [36]): template identiﬁcation,
target template alignment, model construction and model evaluation (Figure 1.2).
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Figure 1.1: The two areas of sequence alignments. Two sequences are practically guaranteed to fold
into the same structure if their length and percentage sequence identity fall into the region above
blue line. For example, two sequences with 80 amino acids, 40% of which are identical, exhibit very
high probability that they will fold into the same structure (red circle) (Figure taken from Protein
Structure and Function by Gregory A. Petsko and Dagmar Ringe, New Science press, 1999-2004).
1.1 Template selection
The selection of the template is the initial step. The sequence of interest (the target sequence) is
used as the query for search of proteins with known 3D structures (the templates) in the structure
databases, like PDB [1, 2]. Diﬀerent database search techniques are available on the web to facilitate
identiﬁcation of the templates [40, 41, 42]. The simplest method is based on serial pairwise sequence
alignments that compares the target sequence with each of the database sequences independently and
gives a set of possible homologs. Frequently used programs based on this method are BLAST [40, 43]
and FASTA [42]. In the present work the BLAST method was used to search for templates in the
PDB database [1, 2].
1.1. TEMPLATE SELECTION 9
Figure 1.2: Steps in comparative protein structure modeling. See text for description.
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Figure 1.3: A: The BLAST algorithm parses protein sequences into 3 letter "words" and for every
sequence in the query identiﬁes database sequences with word matches that have a certain minimum
score. B: When a high score match for a word is found, BLAST extends the sequence comparison
between a query and the hit in both directions.
1.1.1 BLAST (Basic Local Alignment Search Tool)
The BLAST algorithm is a heuristic program, which means that it relies on some smart shortcuts
to perform the search faster. BLAST performs "local" alignments. Most proteins in nature have
functional domains often being repeated within the same protein as well as across diﬀerent proteins
from diﬀerent species. The BLAST algorithm is tuned to ﬁnd these domains or shorter stretches of
sequence similarity. If instead BLAST would align the entire lengths of two sequences fewer similarities
would be detected, especially with respect to domains and motifs.
The alignment in BLAST runs through diﬀerent steps (Figure 1.3). First, all sequences with no
relevance for the alignment process are ﬁltered out, e.g. nucleotide sequences are hidden when protein
sequence alignment is performed. Next, all possible 3-letter words in the query protein sequence are
identiﬁed. Then, for each word from the query sequence a list of similar words is built and scored with
substitution matrices (Figures 1.4). Words with score T≥13 remain in the list of possible matching
words, while those with lower scores are discarded (Figure 1.3A). The BLAST program scans the
database sequences for the remaining high-scoring query words. All matches are scored again with
the substitution matrices. If a high-score match is found in the database, it is used as seed for a
possible ungapped alignment between the query and database sequences, by extending the seed in
both directions (Figure 1.3B). The alignment is extending until the optimal accumulated score is
lower than a cutoﬀ score deﬁned by the user.
The quality of a pairwise sequence alignment is evaluated by the "20x20 substitution matrix", which
assigns a score for aligning any possible pair of residues. Pairs of amino acids which are identical or
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physicochemically similar are scored higher than amino acids with very diﬀerent properties (Figure
1.4). The two most used substitution matrices are PAM (Percentage of Acceptable point Mutations)
[44] and BLOSUM (BLOck SUbstitution Matrices) [45], that are based on an analysis of the frequency
with which a given amino acid is observed to be replaced by other amino acids among proteins with
aligned sequences.
Figure 1.4: A symmetric substitution matrix used by alignment algorithms. The values along the
diagonal are the highest, since they represent conserved residues. Positive scores are assigned also for
the exchanges between residues with similar physicochemical properties (E.g. W > F, Y; V > I; K
> R), while scores for residues that diﬀer in their chemical properties are negative.
Another widely used and more sensitive set of techniques (e.g. PSI-BLAST [43]) relies on multiple
sequence comparison. PSI-BLAST iteratively expands the set of homologs of the target sequence. For
a target sequence an initial set of homologs from a sequence database is collected, a weighted multiple
alignment is made from the query sequence and its homologs, a position speciﬁc scoring matrix is
constructed from the alignment, and the matrix is used to search the database for new homologs.
These steps are repeated until no new homologs are found.
The advantage of multiple sequence comparison techniques is that they result in larger number of
potential templates and they identify better templates for sequences that have only distant relationship
to any solved structure. Once the list of template candidates is collected, it is necessary to choose
the most appropriate template(s) for a given modeling problem. The following factors should be
considered:
 higher sequence similarity between the target and the template leads to more accurate models
 multiple sequence comparison of subfamilies of the target and template protein family might
identify the template closest to the target sequence
 take into account known features that determine protein structure, like conserved residues im-
portant for ligand binding, quaternary interactions, salt bridges etc.
 choose the template with the highest experimental quality (resolution, R-factor)
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1.2 Target-template alignment
The accuracy of the models depends highly on the target-template sequence identity as well as on the
alignment. When the target and template share more than 40% of sequence identity, the alignment
is often correct and the models tend to be reliable. When the sequence identity between the target
and template falls bellow 30%, the alignment is full of gaps and the predictive power of the modeling
method is limited.
When a template is chosen a pairwise sequence alignment has to be performed using a speciﬁc
method, because database searching methods do not give an optimal alignment. As a specialized
alignment method often used is the ClustalW program [46, 47]. The basic multiple alignment algorithm
consists of three main stages: (i) all pairs of sequences are aligned separately in order to calculate a
distance matrix giving the divergence of each pair of sequences; (ii) a guide tree is calculated from the
distance matrix; (iii) the sequences are progressively aligned according to the branching order in the
guide tree.
The target-template alignment obtained as a result of ClustalW calculation is further improved
manually based on structural data of the template. In particular all gaps are removed from secondary
structure tracts, from buried regions and between two residues that are far away from each other.
The multiple sequence alignment of the proteins belonging to the same family or subfamily can often
improve the alignment due to the additional information about conserved residues important for
structure and/or function of the protein. If the target and the template share very low sequence
identity it is worth to build diﬀerent models based on diﬀerent alignments and then to choose best
alignment according to the structural evaluation of the model. It is important to be aware that no
current modeling procedure is able to recover from an incorrect alignment. Therefore it is worth to
spend time trying to align the target and the template as good as possible. Multiple alignments are
usually more reliable than pairwise alignments.
1.3 Model construction
Diﬀerent programs [48, 49, 50] and web servers [51, 52] are nowadays available for building structural
models of the proteins based on target-template alignment. All models presented in this work were
modeled by program MODELLER [48]. It represents an automated approach to comparative protein
modeling by satisfaction of spatial restraints. As input ﬁles the target-template alignment and spatial
coordinates of the template are necessary. The target sequence is then aligned to the 3D structure
of the template followed by the calculations of distance and dihedral angle constraints. The obtained
spatial restraints are combined with stereochemical restraints on bond lengths, bond angles, dihedral
angles and nonbonded contacts calculated by CHARMM22 [53] force ﬁeld to an objective function.
Finally the model is built by optimizing the objective function in Cartesian space. There is a possibility
to add to the program-derived restraints, the other spatial restraints known from diﬀerent experimental
studies (NMR, ﬂuorescence spectroscopy, site-directed mutagenesis...) what improves the accuracy of
the models. Therefore modeling by satisfaction of spatial restraints is widely used and seems to be
the most promising method in comparative modeling.
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1.4 Evaluation of the models
The ﬁrst step in the model evaluation is a check of the overall fold and structural features of the models
predicted with homology modeling. The model is compared to the fold of the template. Obviously,
there must be no knots in the topology, buried residues should be mostly hydrophobic. The fold of
a model can be assessed by available experimental data and by conservation of structurally and/or
functionally important residues.
Then, the Ramachandran plot is visualized and RMSD between the target an the template is
calculated. The main chain conformations have to be in the acceptable regions of the Ramachandran
plot. RMSD depend on the sequence identity, and can be is low as 1 Å if the SI is high and as high
as 4-5 Å if the SI is less than 30%.
Furthermore, it is important that the model has a good stereochemistry. One of the programs that
provide stereochemical analysis is PROCHECK [54, 55], that gives an output with the data of bond
lengths, bond angles, peptide bond and side-chain conformations. PROCHECK program compares
the values of these parameters in the modeled structure to the known parameters of the high resolution
protein structure from which the model was constructed. Therefore, large deviations from most likely
values are interpreted as strong indicators of errors in the model. If the errors are observed, the
structure is introduced to the further reﬁnement.
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Chapter 2
Molecular docking
Molecular docking is a computational procedure that predicts binding mode of a ligand in its target
protein. This is achieved by minimizing a scoring function which describes the interactions between
ligand and target with respect to the atomic positions of the to moieties.
In this work, GOLD 3.0.1 [56, 57, 58] and AutoDock 3.0 [59] programs were used to predict ligand-
protein interactions, while HADDOCK 2.0 program [60, 61] was utilized for building protein-protein
complexes.
2.1 Ligand-protein docking
GOLD (Genetic Optimization for Ligand Docking) [57, 56, 62] is a program used for docking of small
ﬂexible compounds to the protein binding site. GOLD uses an island-based GA search strategy and
includes rotational ﬂexibility for selected receptor hydrogen along with full ligand ﬂexibility. It has two
implemented scoring functions, GoldScore and ChemScore, and a possibility for user deﬁned scoring
function. In this work GOLD 3.0.1 was used.
AutoDock [59] uses a genetic algorithm as a global optimizer combined with energy minimization
as a local search method. The ligand is ﬂexible, while the receptor is rigid.
2.1.1 Search Algorithms
The search of a pose of a ligand in a docking problem is addressed in two essentially diﬀerent ap-
proaches: (1) a full solution space search (2) a gradual guided progression through solution space. The
ﬁrst scans the entire solution space in a predeﬁned systematic manner [63]. In contrast, the second
either scans only part of the solution space in a partially random and partially criteria-guided manner,
or generates ﬁtting solutions [63]. The second approach consists mainly of Monte Carlo (MC), sim-
ulated annealing, molecular dynamics (MD), and evolutionary algorithms such as genetic algorithms
(GA) and Tabu search. The two docking programs used in this work, GOLD and AUTODOCK,
search for optimal ligand binding modes inside a speciﬁc binding pocket using a genetic algorithm
[64, 65].
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2.1.1.1 Genetic Algorithms
Genetic algorithms (GA) [64, 65] are based on the language of natural genetics and biological evolution.
They search for possible ligand binding modes by representing the ligand conformations in a modular
way, using operations similar to mutations and crossover. The quality of the results is a function
of the starting genes, the number of evolutionary events, i.e., the mutations and crossover, and the
scoring function to pick the more favorable conformers.
The GA begins with an initial population, that is a set of chromosomes (ligand binding modes,
chosen randomly). Chromosomes are deﬁned by genes (variables) corresponding to the ligand trans-
lation (x, y, z coordinates of the center of mass), ligand orientation (rotation angles) and ligand
conformation (torsion angle of each ligand rotatable bond). The population goes through a process
of ﬁtness evaluation: each chromosome is assigned a score based on a function which approximately
estimate the free energy of binding (see Sections 2.1.2.1 and 2.1.2.2).
Once the initial population is evaluated, two chromosomes are selected as parents and starting
from them a new population is built. A probability to become parent chromosome grows with the
ﬁtness score. The oﬀspring chromosomes are obtained by a crossover and/or mutation processes on
the parent chromosomes (Figure 2.1). In crossover the chromosomes of the parents are broken into
two pieces at the same gene positions, then the ﬁrst part of one chromosome is combined with the
second part of the other chromosome, and viceversa, resulting in two children. Mutations randomly
modify one or more selected gene(s) in the oﬀspring chromosomes. The new children replace their
parents in the population that enters a new run of algorithm. The whole cycle is repeated until some
number of generations are completed or until some condition (RMSD, δG) is satisﬁed.
Figure 2.1: Scheme of crossover and mutation process. Let us assume two parent chromosomes:
parent1 and parent2. After the crossover, the resulting children have ﬁrst part of genes from parent1
and second part of genes from parent2. Mutations (highlighted in yellow) that may follow the crossover
mutate a selected gene(s) in the oﬀspring chromosome (e.g. in child1 genes 3 and 13 were mutated to
genes 6 and 8).
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2.1.1.2 Island-based genetic algorithm
In GOLD a so-called island-based genetic algorithm is employed (Figure 2.2). It means that rather
than manipulate only one large population of chromosomes (as described in Section 2.1.1.1), several
subpopulations (i.e. islands) are considered and individual chromosomes can migrate among them.
This feature improves eﬃciency of the search. In addition, information about hydrogen bonds between
ligand and receptor is also encoded in the chromosome. The ligand-receptor hydrogen bonds are
matched with a least squares ﬁtting protocol to maximize the number of inter-molecular hydrogen
bonds.
Figure 2.2: Scheme of genetic algorithm used in GOLD program
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2.1.1.3 Lamarckian genetic algorithm
The Autodock uses a genetic algorithm (as described in section 2.1.1.1) in which is implemented a local
search method that allows to minimize the scoring function of selected individuals. The optimized
atomic coordinates (phenotype) are stored back in the chromosome. The new chromosome enters
then into the new iteration of crossover and mutation of the genetic algorithm. Due to the transfer of
information from phenotype to chromosome this algorithm is called Lamarckian.
Figure 2.3: Scheme of genetic algorithm used in Autodock program.
2.1.2 Ranking of the solutions - Scoring functions
Scoring functions estimate the energetics associated with ligands binding to their target. The purpose
of the scoring function is to discriminate between correct native solutions with low RMSD from the
crystal and other docked complexes within a reasonable computation time. Although scoring functions
may be formally deﬁned as free energies, here they are only used to predict ligand binding poses.
2.1.2.1 GOLD scoring functions
The GOLD program has implemented two scoring functions, ChemScore [62] and GoldScore [57, 56].
The ChemScore scoring function was parametrized against experimental binding aﬃnities data and
gives as a result estimated binding aﬃnity of the docked ligand. The ChemScore scoring function
estimates the total binding free energy as a sum of diﬀerent components (hydrogen bonding, metal
and lipophilic interactions and loss of conformational entropy of the ligand upon binding):
∆Gbind = ∆G0 +∆Ghbond +∆Gmetal +∆Glipo +∆Grot
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The ﬁnal ChemScore value is obtained by adding in a clash penalty and internal torsion terms,
which militate against close contacts in docking and poor internal conformations. Covalent and
constraint scores may also be included.
ChemScore = ∆Gbind + Pclash + cinternalPinternal + (ccovalentPcovalent + Pconstraint)
The GoldScore scoring function is calculated as a sum of the protein-ligand hydrogen-bond energy,
the protein-ligand van der Waals energy, the ligand internal van der Waals energy and ligand torsional
strain energy. The contribution of ligand intramolecular hydrogen bonds can be added. ChemScore
and GoldScore are about equally reliable. However, based on our experience, ChemScore performs
better when lipophilic interaction between the ligand and receptor are prevalent, while GoldScore gives
better results for the complexes between the polar ligand and receptor (hydrogen bond interactions).
2.1.2.2 Autodock scoring function
In AutoDock the implemented scoring function is deﬁned as an empirical binding free energy function:
∆G = ∆GvdW
∑
i,j
(
Aij
r12ij
− Bij
r6ij
)
+∆Ghbond
∑
i,j
E(φ)
(
Cij
r12ij
− Dij
r10ij
)
(2.1)
+∆Gelec
∑
i,j
qiqj
ε(rij) rij
+∆GtorNtor +∆Gsol
∑
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(SiVj + SjVi) e(−r
2
ij/2σ
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The summations are performed over all pairs of ligand atoms, i, and protein atoms, j, in addition
to all pairs of atoms in the ligand separated by three or more bonds. rij is the distance between
the atoms, φ is the H-bond angle, and qi is the electrostatic charge of atom i. All ﬁve ∆G terms
on the right hand side are coeﬃcients empirically determined using linear regression analysis from
a set of thirty protein-ligand complexes with known binding constants. The ﬁrst three terms are in
vacuo interaction terms, namely Lennard-Jones dispersion, directional hydrogen bond and screened
Coulomb electrostatic potential. ∆Gtor is a measure of the unfavorable entropy of ligand binding due
to the restriction of conformational degrees of freedom, and Ntor is the number of sp3 bonds in the
ligand. The last term approximately accounts for the desolvation free energy upon ligand binding.
For each atom in the ligand, fragmental volumes of surrounding protein atoms (Vj ) are weighted by
an exponential function and then summed, evaluating the percentage of volume around the ligand
atom that is occupied by protein atoms. This percentage is then weighted by the atomic solvation
parameter of the ligand atom (Si) to give the desolvation energy.
2.2 Protein-protein docking
HADDOCK 2.0 (High Ambiguity Driven protein-protein Docking) [60, 61] is a docking algorithm
which can handle protein-protein docking. The HADDOCK docking protocol has three steps:
(i) randomization of orientations and rigid body energy minimization
(ii) semirigid simulated annealing in torsion angle space
(iii) ﬁnal reﬁnement in Cartesian space with explicit solvent.
In the randomization step both molecules, A and B, are far apart and do randomly rotate around
their center of mass. Then rigid body energy minimization is performed: ﬁrst both macromolecules
are allowed to rotate to minimize the intermolecular energy function. Then both translations and
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rotations are allowed, and the two molecules are docked by rigid body energy minimization. The
second step consists of simulated annealing reﬁnements in which the side chains and the backbone
at the interface are allowed to move to allow for some conformational rearrangements. The resulting
structures undergo then steepest decent energy minimization. The ﬁnal step consists of gentle MD
simulation reﬁnement in a shell of TIP3P [66] waters.
HADDOCK uses a physically-based interaction force ﬁelds to drive the docking process. The
interaction energies are evaluated by full electrostatic and van der Waals energy terms with an 8.5
Å distance cutoﬀ using the OPLS [67] force ﬁeld. The ﬁnal structures are clustered using the pair-
wise backbone RMSD at the interface. Clusters are analyzed and ranked according to their average
interaction energies (sum of Eelec, EvdW , EAIR) and their average buried surface area.
To get accurate docking predictions, HADDOCK takes as input also biochemical and/or biophys-
ical experimental data, like mutagenesis data or information about chemical shift perturbation upon
binding. Interface interactions are deﬁned by Ambiguous Interaction Restraints (AIR) that involve
the active and passive residues. Active residues are for example those detected by mutagenesis to be
involved in protein-protein interactions or those showing a signiﬁcant chemical shift perturbation upon
complex formation. Passive residues are their closest solvent accessible neighbors. AIR are deﬁned
as an ambiguous intermolecular distance diAB between each active residue from molecule A and both
active and passive residues from molecule B (and inversely for molecule B):
deffiAB = (
Natoms∑
miA=1
NresB∑
k=1
Natoms∑
nkB=1
1
d6miAnkB
)−
1
6
where Natoms is the number of all atoms in selected residue and NresB is the sum of active and
passive residues in the molecule B. The AIR are satisﬁed every time the distance of an atom m from
active residue i of molecule A and an atom n of passive or active residue k of molecule B is shorter
than 2 Å.
Chapter 3
Molecular dynamics
Molecular dynamics (MD) is a computer simulation technique that enables the theoretical study
of (biological) molecules. Given the initial positions of the atoms in the macromolecule and in the
solvent, MD calculates the time evolution of the system. MD simulations provide detailed information
on the ﬂuctuations and conformational changes of proteins and nucleic acids. These methods are now
routinely used to investigate the structure, dynamics and thermodynamics of biological molecules and
their complexes. They are also used in the determination of structures from x-ray crystallography and
from NMR experiments.
MD is based on the Born-Oppenheimer approximation, i.e. the nuclei can be treated as classical
particles and the electronic degrees of freedom can be integrated out. This approximation relies on
the large diﬀerence between the mass of the nuclei (heavy) and that of the electrons (light). Under
these greatly simplifying assumptions, atoms are treated as point masses and the dynamics of the
system can be described by Newton's second law:
~Fi(t) =
d2~ri(t)
dt2
·mi = −dU
d~ri
(3.1)
where is ~ri the position of the ith atom, ~Fi the force acting on it, and U is the potential energy of the
system (i.e. the force ﬁeld). In this way, knowing the initial structure (by experiments or by computer
modeling) and providing an initial velocity distribution consistent with the temperature simulated, it
is possible to compute the time evolution of the system. Average values of several physico-chemical
properties can be evaluated from the resulting trajectory [68].
The MD run consists of several steps:
1. Deﬁne the initial positions ~ri and velocities ~vi of all atoms, the force ﬁeld U , and the boundary
conditions P, T .
2. Compute the force ~Fi acting on each atom.
3. Solve Eq. 3.1 and update the conﬁguration of the system.
4. Write the new positions, velocities, energies, . . . , etc.
5. Back to point 2
In this work, the Gromacs simulation package [69] has been used. In the following are described the
main MD algorithms and the form of the force ﬁeld.
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3.1 Equations of motion
MD simulations consist in the numerical, step-by-step solution of the classical equations of motion
Eq. 3.1. The integration time step ∆t is chosen at the beginning of the simulation and it remains
unchanged during the run. The time step must be small enough to allow describing the fastest motions
of the system: ∆t ≤ 0.5 fs is normally used when bonds involving hydrogens are allowed to stretch.
Bond stretching is of little interest in most cases, therefore bonds are constrained to their equilibrium
lengths using the LINCS algorithm [70]. In this way a larger∆t ≤ 1.5/2 fs can be employed while still
retaining a good accuracy. Nowadays it is common to simulate biological systems of ∼ 50000 atoms
for ∼ 100 ns.
The most used algorithms for the integration of the equations of motion are the so called Verlet [71]
and Leap-Frog algorithms [72]. In both algorithms the positions of each atom are expressed by Taylor
expansions for the time increment ∆t. The Leap-Frog algorithm however provides more accurate
velocities [68] and it has been used in this thesis. Updated positions and velocities are computed in
the following way:
~vi(t+∆t/2) = ~vi(t−∆t/2) + ~Fi(t)mi ·∆t (3.2)
~ri(t+∆t) = ~ri(t) + ~vi(t+∆t/2) ·∆t (3.3)
which makes use of the positions and forces at time t and velocities at time t+∆t/2. The update of
positions and that of velocities leaps each other: ﬁrst, the velocities are calculated at half time step,
then these are used to calculate the positions at one time step. A disadvantage of this algorithm is
that velocities are not calculated at the same time as positions, but this can be solved by the following
approximation:
~vi(t) =
~vi(t−∆t/2) + ~vi(t+∆t/2)
2
(3.4)
In this way, the kinetic and potential energies can be summed at the same time t to compute the total
energy.
3.2 Force ﬁeld
The potential energy U in Eq. 3.1 is a function of the atomic coordinates of all atoms and determines
the forces among them. In MD simulations of biological systems usually empirical force ﬁelds U
are employed, whose parameters are obtained from gas-phase experiments and accurate quantum
mechanical calculations [73]. In this work the Amber parm99 force ﬁeld was used [74].
The force ﬁelds for biological systems have the following typical form:
U = Ebonds + Eangles + Edihedrals + Evdw + Eelect (3.5)
Diﬀerent terms are summed which correspond to bond distances stretching (Ebonds), bond angles
bending (Eangles), bond dihedral or torsion angle (Edihedrals), van der Waals potential (Evdw) and
electrostatic potential (Eelect). The ﬁrst three terms are considered to be the intramolecular bonding
interactions, as they involve multiplets of atoms connected by chemical bonds. The last two terms
represent the non-bonded interactions between atoms. The speciﬁc form of each of these terms is
shown below:
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Ebonds =
∑
bonds
1
2kr(r − req)2 (3.6)
Eangles =
∑
angles
1
2kθ(θ − θeq)2 (3.7)
Edihedrals =
∑
dihedrals
1
2Vn(1 + cos(nϕ)− γ) (3.8)
Evdw =
atoms∑
i<j
(
Aij
r12
ij
− Bij
r6
ij
)
(3.9)
Eelec =
atoms∑
i<j
qiqj
4piε0rij
(3.10)
In the bonding interactions, the bond stretching and angle bending terms are represented as
harmonic energy functions where req and θeq refer to equilibrium bond lengths and angles, kr and kθ
being the vibrational constants. The equilibrium values of the bond and angle parameters are usually
derived from structural databases, while the force constants are derived from infrared spectroscopy.
In the third term, Vn is the torsional barrier corresponding to the nth barrier of a given torsional
angle with phase γ: dihedral parameters are calibrated on small model compounds, comparing the
energies with those obtained by quantum chemical calculations. Improper dihedral angles are added
to take into account quantum eﬀects that are not present in U as, for example, to preserve planarity
in aromatic rings.
In the non-bonded interactions, the van der Waals potential is described by a Lennard-Jones
potential, containing an attractive and a repulsive term: the parameters are deﬁned so as to repro-
duce chemico-physical properties (e.g., densities, enthalpies of vaporization, solvation free-energies)
of organic liquids. The electrostatic energy is evaluated by assuming the dielectric constant ε equal
to 1 (vacuum value), and using the restrained electrostatic potential model [75] to deﬁne partial
atomic point charges: in this model, charges are assigned to the atom-centered points so as to ﬁt the
electrostatic potential derived from quantum chemistry calculations for a set of small representative
molecules. Van der Waals and electrostatic interactions are calculated between atoms belonging to
diﬀerent molecules or for atoms in the same molecule separated by at least three bonds. In principle,
the non-bonded interactions involve all pairs of atoms in the system, and they are the most expensive
part of a MD calculation. In practical applications, however, the number of calculated interactions are
limited by a predeﬁned cutoﬀ distance, so the non-bonded terms are calculated only between atoms
separated by a distance not larger than the cutoﬀ. For the van der Waals potential, this truncation
introduce only a small error in the energy. This is not the case for the electrostatic potential, because
the Coulomb interaction between charges qi and qj decays slowly with distance. Hence it can not
be truncated, but when periodic boundary conditions are used, it is computed with eﬃcient schemes
such as Particle Mesh Ewald [76] (see Section 3.5) in conjunction with periodic boundary conditions
(Section 3.3), which approximate the exact result to an acceptable error similar to the error in the
van der Waals potential.
3.3 Periodic boundary conditions
MD simulations are usually performed under periodic boundary conditions (PBC), to minimize bound-
ary eﬀects and to mimic the presence of the bulk environment. In this approach, the system is
surrounded with replicas of itself in all directions, to yield an inﬁnite periodic lattice of identical cells.
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When a particle moves in the central cell, its periodic image in every other cell moves accordingly
(Figure 3.1). As one molecule leaves the central cell, its periodic image enters from the opposite side.
Figure 3.1: Periodic boundary conditions. As a particle moves out of the simulation box, an image
particle moves in to replace it. In calculating particle interactions within the cutoﬀ range, both real
and image neighbors are included.
The PBC are taken into account only in the calculation of non-bonded interactions between atoms
belonging to diﬀerent molecules, and, if the potential range is not too long (the cutoﬀ radius must not
exceed half of the box side), the minimum image convention is adopted. This means that each atom
interacts only with the nearest atom or image in the periodic array.
When a macromolecule is simulated in solution, this convention is not appropriate, since in principle
the macromolecule should not interact with its periodic images. This means that the length of each
box vector must exceed the length of the macromolecule in the direction of that edge plus twice the
cutoﬀ radius.
3.4 Neighbors list
Computing the non-bonded contribution to the interatomic forces in an MD simulation involves, in
principle, a large number of pairwise calculations. Let us assume that the interaction potentials are
short ranged, i.e. they vanish for rij > rcut. When this happens, the program skips the expensive
force calculation, and considers the next candidate pair of atoms. Nevertheless, the time to examine
all pair separations is proportional to the number of distinct pairs and this still consumes a lot of
computer time.
Some economies result from the use of lists of nearby pairs of atoms. The potential cutoﬀ sphere
of radius rcut, around a particular atom is surrounded by a `skin', to give a larger sphere of radius rlist
as shown in Figure 3.2. At the ﬁrst step in a simulation, a list is constructed of all the neighbors of
each atom, for which the pair separation is within rlist. Over the next few MD time steps, only pairs
appearing in the list are considered for force calculation. From time to time the list is reconstructed:
it is important to do this before any unlisted pairs have crossed the safety zone and come within
interaction range.
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Figure 3.2: The potential cutoﬀ range (rcut, solid circle), and the list range (rlist, dashed circle), are
indicated. The list must be reconstructed before particles originally outside the list range (black) have
penetrated the potential cutoﬀ sphere.
3.5 Long range forces
Long range forces are usually deﬁned as those in which the spatial interaction falls oﬀ no faster than
r−d where d is the dimensionality of the system (d = 3 in common situations). In this category are
the charge-charge interactions between ions (V (r) ≈ r−1). These interactions are problematic for the
simulations, since their range is greater then half the box length. There are several ways to handle
this problem.
3.5.1 Electrostatics
The Ewald sum [77] is a technique for eﬃciently summing the interactions among ions and all their
periodic images. The potential energy can be written as
V =
1
2
∑
n
′
 1
4piε0
N∑
i=1
N∑
j=1
qiqj
rij ,n
 (3.11)
Where qi and qj are the charges, n is the box index, rij is the distance between the charges and
the prime indicates that we omit i = j for n = 0. Due to the long-range nature of the potential, this
sum is conditionally convergent, and converges very slowly. Therefore, a very large number of images
is required to achieve a reliable estimate of V . The idea behind the Ewald method is to surround
every point charge by a charge distribution of equal magnitude and opposite sign %−, which spreads
out radially from the charge. This distribution is conveniently taken to be Gaussian
%Gi (r) = qi
(α
pi
) 3
2
exp
(
−α |ri + nL|2
)
(3.12)
here α is an arbitrary parameter which does not determine the ﬁnal result, but that can be adjusted to
optimize the speed of convergence. In this way an eﬃcient screening is performed, so that interactions
rapidly go to 0 and direct summation is possible. This extra distribution acts like an ionic atmosphere,
to screen the interaction between neighboring charges. The screened interactions are now short-ranged,
and the total screened potential is calculated summing over all molecules. A charge distribution of
the same sign as the original charge, and the same shape as the distribution %Gi (r) is also added.
This canceling distribution reduces the overall potential due to the original set of charges. In order
to exclude self-interactions the contributions of these three charge densities should not be evaluated
in ri. However, it is convenient to keep self-interactions due to the canceling charge distribution %+,
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since %+ is in this way periodic and can be represented as a rapidly converging Fourier sum. The
spurious self-interaction can be easily subtracted separately. The canceling distribution is summed in
the reciprocal space. In other words, the Fourier transforms of this distribution are added, and the
total transformed back into real space. Thus, the total charge distribution of the system %(r) may be
rewritten as:
ρ(r) =
∑
i
qiδ (r − ri + nL)
ρ(r) =
∑
i
(
qiδ (r − ri + nL)− ρGi (r)
)
+
∑
i
ρGi (r)
(3.13)
Where the ﬁrst sum (which only produce short ranged potentials) is calculated in the direct space,
while the second is calculated in the reciprocal space:
V = (εdir − εself + εrec) (3.14)
εdir = 12
∑
n
′ N∑
ij
qiqj
|rij+nL|erfc (
√
α |rij + nL|) (3.15)
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α
pi
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q21 (3.16)
εrec = 2piV
∑
k 6=0
∑
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4α
)
k2 qiqj exp (−ik · (r − rj)) (3.17)
where erfc = pi− 12
∫∞
r
exp
(−r2) dx is the complementary error function.
εdir is very similar to Equation 3.11, although the long ranged 1r function is here substituted by
the short ranged erfc(r)r : as a result, the interaction vanishes above a cutoﬀ roughly equal to α−
1
2 , and
for every i and j the interaction can be approximated by only one periodic image term. Typically, α is
chosen such that such truncation error is of the order of 10−5/10−6 of εdir. εself is the self interaction
of the Gaussian charge distributions: it must be subtracted from the total, as the reciprocal space
term εrec contains it, albeit it is a constant number, not depending on the atomic conﬁguration. εrec is
a sum over an inﬁnite number of terms, but the factor k24α ensures a fast convergence in the reciprocal
space, and normally no more than 5/10 wave vectors in each direction are required. Its calculation is
however the most consuming part in the Ewald scheme.
The Particle Mesh Ewald (PME) algorithm [76, 78] allows a fast calculation of the electrostatic
energy. Again, the interaction is split into a short-range part and a long-range part. The short-range
part converges rapidly in real space, and it is evaluated simply as a sum of atom-atom interactions,
like in the Ewald scheme. Instead, the long-range part is evaluated in a more eﬃcient way as a
fast Fourier transform, by representing the atom charges as a charge density ﬁeld on a grid. The
grid spacing is chosen compatibly with the periodic boundary conditions. Both the short-range and
long-range parts can be safely approximated by truncating the summations to few terms. The PME
algorithm is particularly suited to simulate periodic systems with a large number N of atoms, as the
computational cost scales like N log(N).
3.6 Temperature and pressure control
In MD simulations is possible to adopt diﬀerent types of thermodynamics ensembles, which are char-
acterized by the control of certain thermodynamic quantities. The simpler is the microcanonical
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ensemble (NVE), in which the number of particles, volume and total energy are constant. However
the microcanonical ensemble does not correspond to the conditions under which most experiments are
carried out. In experiments typically the pressure and/or the temperature are kept constant, therefore
the canonical (NVT) or the isothermal-isobaric (NPT) ensembles are the most useful. To simulate the
system in such ensembles, thermostat and barostat algorithms are required to control the temperature
and pressure during the MD run. In this work the Berendsen thermostat and barostat were adopted
[79], along with the Nose-Hoover thermostat.
3.6.1 Berendsen thermostat
The instantaneous value of the temperature T (t) of a system with Ndf degrees of freedom is related
to the kinetic energy Ekin via the particles velocities as follows [79]:
Ekin(t) =
N∑
i=1
1
2miv
2
i (t) =
1
2NdfkBT (t) (3.18)
T (t) =
N∑
i=1
miv
2
i (t)
NdfkB
(3.19)
A simple way to alter the temperature is to scale the velocities by a factor λ:
∆T =
N∑
i=1
mi(λvi)
2
NdfkB
− miv2iNdfkB (3.20)
∆T = (λ2 − 1)T (t) (3.21)
If T0 is the desired temperature and T (t) is the current temperature, the time variation of temperature
is deﬁned as:
dT (t)
dt
=
T0 − T (t)
τT
, ∆T = ∆t
T0 − T (t)
τT
(3.22)
It follows that:
λ(t) =
√
1 +
∆t
τT
(
T0
T (t)
− 1
)
(3.23)
The factor λ is used to scale the velocities at each time-step, in order to relax the temperature toward
the desired temperature value T0. The relaxation rate is controlled by the time coupling constant
τt, which should be small enough to achieve the required temperature, but large enough to avoid
disturbance of the physical properties of the system by coupling to the bath.
3.6.2 Berendsen barostat
The Berendsen algorithm to control the pressure of the system [79] is similar to the Berendsen ther-
mostat. In this case, the algorithm scales the coordinates ~riand the box vectors h = (~a,~b,~c) with a
matrix µαβ :
ri,α →
∑
β
µαβri,β , hαβ →
∑
γ
µαγ hγβ . (3.24)
The eﬀect is a ﬁrst-order kinetic relaxation of the instantaneous pressure P (t) towards a reference
pressure P0, with a time constant τP that can be speciﬁed as an input parameter. The basic equation
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for the Berendsen algorithm barostat is:
dP (t)
dt
=
P0 − P (t)
τP
(3.25)
and the scaling factor µ(t) for the atoms positions and box vectors is
µαβ = δαβ − βαβ ∆t3τP [P0,αβ − Pαβ(t)] (3.26)
Where β is the isothermal compressibility, P (t) is the instantaneous pressure, P0 is the target pressure
and τP is the pressure coupling constant.
3.6.3 Nose-Hoover thermostat
In the Nose-Hoover scheme [80, 81] the equation of motion of each atom is modiﬁed by a time-
dependent frictional term ξ(t)~vi(t) as:
~ai(t) =
∂~vi(t)
∂t
=
~fi
mi
− ξ(t)~vi(t) , (3.27)
∂ξ(t)
∂t
=
(T (t)− T0)
Q
,
where the strength of the coupling Q (often called the mass of the oscillator ξ(t)) is speciﬁed before
the simulation, and it is linked to the time constant through the relation:
Q =
τ2T0
4pi2
, (3.28)
but the actual implementation is often written as:
~vi(t+∆t/2) =
(
1 +
1
2
ξ(t)∆t
)−1((
1− 1
2
ξ(t)∆t
)
~vi(t−∆t/2) +
~fi(t)
mi
∆t
)
, (3.29)
where (1 − (1/2)ξ(t)∆t)/(1 + (1/2)ξ(t)∆t) is used as an approximant of (1 − ξ∆t) around ξ∆t ' 0,
which prevents unphysical, divergent trajectories for ξ(t) in situations when |ξ∆t| > 1.
3.7 Analysis of molecular dynamics trajectories
Several structural and ﬂuctuation properties were calculated in this thesis starting from molecular
dynamics trajectories.
3.7.1 Root Mean Square Displacement (RMSD)
The displacement of atoms or groups of atoms along the trajectory can be estimated by the Root
Mean Square Displacement (RMSD). The RMSD of a set of N atoms at time t, with respect to a
reference conformation (e.g. the initial conformation), reads:
RMSD(t) =
√∑N
i=0 |~ri(t)− ~r0i |2
N
(3.30)
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Where
∣∣~ri(t)− ~r0i ∣∣ is the displacement of the ith atom at time t from the reference position r0i . An
increase of the RMSD indicates that the protein moves to a conformation diﬀerent from the initial
structure and thus may suggest that a conformational change is occurring.
3.7.2 Root Mean Square Fluctuation (RMSF)
Similar to the previous analysis is the calculation of the ﬂuctuations of an atom or a group of atoms
from the average positions, according to the formula:
RMSFi =
√〈
(~ri − 〈~ri〉)2
〉
(3.31)
where ~ri is the position vector of the ith atom and the brackets indicate average over the trajectory.
This analysis gives clues about the most mobile regions of the protein, which will display a large value
of RMSF .
Comment on free-energy calculations
In the projects presented in Chapters 5 and 7 part of the calculation was carried out by other members
of the biomolecular simulation group of SISSA (see also Introduction and Outline of the thesis).
These are the metadynamics free-energy calculations which have been performed by F. Pietrucci for
bestrophin and X. Biarnes for the prion protein. For this reason the theory of free-energy calculations
is not presented here but in the computational section of the corresponding chapters.
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Part II
Calcium-gated ionic channels
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Chapter 4
Molecular modeling of hBK Ca2+
binding domains
Abstract
Human big conductance Ca2+- and voltage-gated K+ channels (hBKCa) are putative drug targets
for cardiovascular, respiratory and urological diseases. Here we have used molecular simulation and
bioinformatics approaches to construct models of two domains important for Ca2+ binding and chan-
nel gating, namely the regulator of conductance for K+ (RCK1) domain and the so-called calcium
bowl (Ca2+ bowl). As templates for RCK1 were used the corresponding domains from a K+ chan-
nel from E. coli and the K+ channel from Methanobacterium thermoautothropicum (MthK). Ca2+
bowl was modeled upon the structure of the human thrombospondin-1 C-terminal fragment. The
domain underwent 70-ns MD simulations in aqueous environment. The relevance of these models for
interpreting the available molecular biology data is then discussed.
4.1 Introduction
Ca2+- and voltage-gated big conductance K+ channels (BKCa channels) are expressed by a variety
of eukaryotic organisms. In mammals, they play an important role in muscle contractions, neuronal
excitability, hormones and neurotransmitters release [7]. They are putative targets for pharmaceutical
intervention for a variety of diseases, including cardiovascular, respiratory, urological diseases along
with idiopathic epilepsy and ischemic reperfusion injury [8, 82].
BKCa channels open upon an increase of intracellular Ca2+ ions (up to a concentration spanning
0.5 µM - 50 mM [83]) along with an increase in the membrane electric potential [84]. Molecular
biological experiments have established that these channels are homotetramers [85], composed of
either α or α and β subunits along with four cytoplasmic domains: RCK1 and RCK2 (Regulate
the Conductance of K+), the Ca2+-binding domain, the so-called calcium-bowl (Ca2+ bowl) and
the serine proteinase-like domain (SPLD) (Figure 4.1). The transmembrane region of the α subunit
includes the S4 helix as the voltage sensor responsible for voltage sensitivity [86], the pore region
through which K+ ions ﬂow out of the cell [87] and the S0 helix (present only in this channel) that places
the N-terminus outside the cell [88]. Ca2+ ions are bound to the cytoplasmic domains: Ca2+ binding
to two putative Ca2+-binding sites in the RCK1 domain causes the gating of the channel [89, 83, 90].
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A linker then connects RCK1 to RCK2, which is also important for the gating [91, 92]. Finally, a
Ca2+ bowl domain is present. Mutations in this domain reduce the ability of low concentration of
Ca2+ to activate the channel [93].
Besides the α subunit, there is also a β subunit (Figure 4.1) [85], which exists in four diﬀerent
subtypes, β1 - β4 [94]. The most studied one is the β1 subunit in smooth muscle BKCa channels
[95, 96]. The β1 subunit increases Ca2+ sensitivity and decreases voltage sensitivity of BKCa channels
[95].
Figure 4.1: All BKCa channel monomers feature one subunit, which consists of a transmembrane
domain (seven transmembrane-helix bundle and a pore helix), the RCK1, the linker and the RCK2
domains, the Ca2+ bowl (CB) and the SPLD domain [95]. Beside α subunit also β transmembrane
subunit can be present, for which four diﬀerent subtypes are known [94]. The most studied one (β1),
shown here, is present in BKCa channels expressed in smooth muscles [95, 96]
Most of the drugs targeting the protein are believed to bind to the α subunit cytoplasmic domain,
aﬀecting Ca2+ aﬃnity and modulating the interaction with the β subunits [82]. Few ligands interact
with the transmembrane domain [82]. Therefore, structural information of both the transmembrane
and cytoplasmic domains of the α subunit would be of great help for the rational design of ligands
with large aﬃnity for the channel. Unfortunately, such information is still lacking.
Here we have used bioinformatics approaches, along with molecular dynamics (MD) simulations, to
construct structural models for some of these domains. The available molecular biological data for the
channel (see Table 4.1) have been used to validate models of two of the channel domains. Firstly, the
RCK1 domain, employing as templates the correspondent domains of two structurally similar chan-
nels: a K+channel from E. coli (PDB entry: 1ID1) [97] and the K+channel from Methanobacterium
thermoautothropicum (MthK) (PDB entry: 1LNQ) [91] (it is worth noting that the latter is Ca2+-
(and not voltage-) gated). Secondly, the Ca2+ bowl domain was modeled using a two stage strategy
as the sequence analysis per se does not allow identifying the metal binding site(s). For this domain,
we ﬁrst modeled the Ca2+ bowl, using as the template one of the Ca2+-binding domains from human
thrombospondin-1 C-terminal fragment (PDB entry: 1UX6, from A865 to N897) [98], and we then
attempt to identify the metal binding sites by performing MD simulations with Ca2+ ions placed in
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ﬁve diﬀerent locations, these are referred to for clarity as Ca1-Ca5. No attempts are made to construct
tetrameric structures and only isolated RCK1 and Ca2+ bowl domains were considered. The way the
subunits assemble is indeed not known and there are no experiments involving the subunit-subunit
interface, which could help assisting the modeling of the quaternary structure of the protein.
In addition, for the transmembrane region and RCK2, although there are reasonably good tem-
plates (e.g. voltage-gated K+ channel Kv1.2 [99], E. coli K+ channel [97], MthK [91]), molecular
biology data are not available. Therefore we limit the analysis for these domains to the sequence
alignment. For the linker and SPLD, there are not reliable templates presently and they are not
investigated here.
4.2 Computational details
4.2.1 Transmembrane region
hBKCa transmembrane region sequence was aligned to that of Kv1.2 (PDB entry: 2A79) [99] using
the ClustalW program [47].
4.2.2 RCK domain
Two templates were found: the RCK domains in an E. coli K+ channel (PDB entry: 1ID1) [97], which
form a dimer, and those of the MthK channel (PDB entry: 1LNQ) [91], which construct a dimer of
dimers. Both share with RCK1 18% of sequence identity (SI) and 40% of sequence similarity (SS).
We ﬁrst performed a structural alignment between the RCK domains from MthK and E. coli by
using Swiss-Pdb Viewer 3.7 [100]. Then we performed the sequence alignment of RCK1 from hBKCa
against both templates, using the same program. Gaps were manually removed from the secondary
structure element sequence tracts. 3D models were eventually built using MODELLER 6v2 [48]. A
distance restraint between NZ@K513 and CG@D546 atoms was included in the model in order to
form a salt bridge, whose presence has been suggested by the experiments [97].
4.2.3 Calcium bowl
The best template for Ca2+ bowl is the 35 residues long segment of the human thrombospondin-1
C-terminal fragment (PDB entry: 1UX6, from A865 to N897, SI=17%, SS=43%, Figure 4.5) [98], as
shown by a Blast [40] search. It binds ﬁve Ca2+ ions; therefore ﬁve Ca2+ ions were added to the 3D
model of Ca2+ bowl, built as above with MODELLER 6v2 [48], with similar coordination as in the
template. The resulting adduct was inserted in a box of dimensions 46 x 46 x 46 Å3 packed with
3955 water molecules. The system underwent MD simulations using the Gromacs-3.2.1 program [101].
The Amber parm99 [73] and TIP3P [66] force ﬁelds were used for the protein frame with the metal
ions and the solvent, respectively. The model was initially minimized with positional restraints on the
solute with a stepwise (each 100 ps) reduced force constant from 1000 kJ mol−1 nm−2 till 0 kJ mol−1
nm−2 (in steps of 200 kJ mol−1 nm−2). After, an unconstrained MD was carried out for an overall
length of 70 ns. A time step of 2 fs was used. All bond lengths were kept ﬁxed applying the LINCS
algorithm [70]. Temperature (300 K) and pressure (1 bar) were kept constant by coupling the system
to a few Berendsen thermostats [102]. Periodic boundary conditions were applied treating long-range
electrostatic interactions with the particle-mesh Ewald technique [76, 78]using a cut-oﬀ of 10 Å for
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the real part of the electrostatic. The same cut-oﬀ was used for the van der Waals interactions. Pair
lists were updated every 20 steps.
4.3 Results
4.3.1 Transmembrane region
The alignment for the transmembrane region S0-S3 with Kv1.2 turned out to exhibit large gaps,
together with the two missing parts (36 and 12 amino acids) in the structure of Kv1.2; as a result,
we restricted our analysis to the S4-S6 tract (Figure 4.2). The sequence identity for the region from
S4-S6 between hBKCa and Kv1.2 is 21%, while the similarity for the same part is 50% (Figure 4.2).
The following features can be noticed: (i) as expected the GYG ﬁngerprint, highly conserved
signature among K+ channels [103] is located in the selectivity ﬁlter. It is responsible for the high
selectivity of K+ over Na+. (ii) In general, Kv channels have conserved PXP sequence as the gating
hinge in the last part of S6 helix [104, 105, 106, 107, 108]. In hBKCa is conserved just one proline
(P385), which could cause breaks or irregularities in the helix structure and can be therefore considered
as putative gating hinge. However, also G376 in S6 helix, which is conserved among K+channels and
corresponds to G83 in MthK [91] and to G247 in Kv1.2 [99] could be a good candidate for the hinge.
(iii) The S4 helix with its repeats of positively charged residues (Arg) followed by two hydrophobic
residues represents the voltage sensor [86]. In comparison with Kv1.2, hBKCa lacks two positively
charged residues. (iv) Two adjacent rings of four Glu residues are positioned at the entrance of the
intracellular vestibule [87]. These eight Glu's play a key role for the high conductance of the channel
by attracting intracellular K+ ions, concentrated at the entrance of the intracellular vestibule. In
fact, Glu to Gln mutation in either ring decreases single channel current by about 12 pA, whilst the
mutation of all the eight Glu's in the ring cause the conversion to an inwardly rectifying channel
(meaning that the channel current decreases with increasing the voltage) [87].
4.3.2 RCK1 domain
The RCK1 domain starts at the highly conserved 409HIVVC [97] and ﬁnishes at FSMRS580 (Figure
4.3A). The fold of RCK1 model is the Rossmann fold with two additional helices (Figure 4.3B) [97].
The model includes the salt bridge formed by K513 and D546 (Figure 4.3C) as established by molecular
biological experiments [97], which show that mutations K513D or D546K reduce open probability of
the channel. This salt bridge has to be considered as an input in the model, as it does not emerge
from the alignment procedure only.
Two putative Ca2+-binding sites have been identiﬁed [89, 83, 90]. One is formed by D427 and D432
which binds Ca2+ in concentrations at around 10 µM. In fact, D432A produces a marked reduction in
the ability of Ca2+ to shift gating, while D427A mutation exhibits the same behavior as the wild type
channel [83]. In order to identify such binding sites, we scanned a set of Ca2+-binding proteins from
the PDB database. In general Ca2+-binding sites involve three to four negatively charged residues
(see Figure 4.4A), each contributing with either one or both oxygen atoms. In addition, as Ca2+
is usually coordinated with 6-8 oxygen atoms [109] (see Figure 4.4B), water and/or oxygen atoms
from the amino acids backbone or the side chains of Gln and Asn could contribute to the binding.
Therefore, in the high aﬃnity binding site, beside the suggested D427 and D432, D434 and/or D435
may also bind Ca2+. The model supports that D427 and D432 do not bind to the metal ion, although
this has not been ﬁrmly established yet.
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Figure 4.2: Alignment between S4-S6 region of hBKCa and Kv1.2 channel. Structurally and function-
ally important features are shown: (i) positively charged residues in S4, which constitute the voltage
sensor are labeled by stars (*); (ii) GYG as the ﬁngerprint of selectivity ﬁlter is signed by a box [103];
(iii) G376 and P385 as putative gating hinges in hBKCa are depicted by boxes (iv) E386 & E389 that
form the ring of negatively charged residues [87]are denoted with the exclamation mark (!).
Figure 4.4: Number of negatively charged residues (Asp, Glu) (A) and oxygens (B) needed to bind
one Ca2+ ion as determined by the analysis of 87 bonded Ca2+ ions in 20 Ca2+-binding proteins from
PDB database [1].
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Figure 4.3: A: Alignment of the two RCK domains from E. coli and MthK with the corresponding
sequence in hBKCa. The following features are shown using hBKCa notation: (i) salt bridge formed by
K513 and D546 is labeled by stars (*); (ii) putative high aﬃnity Ca2+-binding site [83, 90] composed
by D427 and D432 is depicted by hashes (#); (iii) putative low aﬃnity Ca2+-binding site [89, 83, 90],
constructed by E439, Q462 and E464, is denoted with plus signs (+). B: The model of the RCK1
domain. C: Salt bridge formed by K513 and D546 was included in the model and is consistent with
the molecular biology data [97].
4.3.3 Calcium bowl
The Ca2+ bowl is a crucial domain for Ca2+ binding [110, 111, 90]. Molecular biological exper-
iments show that there are ﬁve adjacent Asp's residues (D959-D963 in the sequence: 945TE...DQ
DDDDDPD...TA979), which most probably bind the metal ions [110, 111]. Beside them, there are
other oxygen-containing residues, which can coordinate Ca2+ as well (Figure 4.5A) [110, 111]. The
model can be formally divided in two segments, one formed by 17 (T945-D961) and the other by 18
(D962-A979) residues. An α-helix is present in the ﬁrst segment, the rest forms a coil. Each segment
bears two Ca2+-binding sites (Ca1, Ca2 and Ca3, Ca4), whereas the ﬁfth one (Ca5) is in between.
Unfortunately, there are no templates sharing high sequence identity with Ca2+ bowl, furthermore
the number of Ca2+ ions binding to it is unknown. The best template for this domain, the human
thrombospondin-1 C-terminal fragment [98] exhibits SI=17% and SS=43% (Figure 4.5A). Therefore
we decided to construct ﬁrst a model based on such template (namely from T945 to A979 in hBKCa)
and then to relax it by NPT MD simulations in aqueous solution. The ﬁve Ca2+ in the template were
added in the corresponding binding sites of the model (Ca1-Ca5) in order to verify if they remained
in these positions during the MD simulation. Obviously, the exact number and the coordination of
Ca2+ bound to the Ca2+ bowl have to be validated against further biochemical experiments.
At the end of the MD run (70 ns), the model structure from T945 to E967 keeps the fold around
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Ca2+ ions, while the part from L968 to A979 is unfolded. Ca2+-binding sites are present in the
structured part of the Ca2+ bowl model. Two Ca2+ ions, Ca1 and Ca3, remain well coordinated
throughout the MD simulations forming well deﬁned binding sites (Figure 4.5B and C), while the
other three (Ca2, Ca4 and Ca5) get partially or completely solvated. Ca1 is bound by D959, D961,
D963 and E967 carboxyl oxygen atoms along with D963, D965 backbone oxygen and one water
molecule. Ca3 is coordinated by E946, D950, D957 and D962 carboxyl oxygen atoms beside the D959
backbone oxygen and a water molecule.
Figure 4.5: A:Alignment between human Thrombospondin-1 and hBKCa Ca2+-binding domain (Ca2+
bowl). The template residues binding Ca2+ ions with the side chain are depicted with the circle 'o';
those binding Ca2+ with the backbone oxygen with 'x'. B: Ca2+-binding sites (Ca1 and Ca3) in the
Ca2+ bowl model after 70-ns MD simulations. Ala mutations of the residues depicted in blue boxes
were experimentally shown to reduce Ca2+ binding for 30% while those in yellow boxes reduced Ca2+
binding for 50% (see also Table 4.1). Water molecules are not shown due to the clarity's sake. C:
Ca2+ coordination number contributed by protein O-donors (red) and water molecules (blue) plotted
as a function of MD simulation time. Ca2+ were deﬁned as bound if their coordination number was
at least 6 and not more than 2 water molecules contributed to their binding.
Ca4 remains coordinated by 5 peptide O-donors and three waters, what we consider as partially
solvated. Ca2 is as well partially dissolved being coordinated by 4 peptide O-donors and four waters,
while Ca5 is completely dissolved after ∼ 9.6 ns. Ca5 solvation may be caused by the fact that in the
initial model Ca5 is bonded to a smaller number of protein ligands than Ca1-Ca4.
Our MD model of Ca2+ bowl appears to be consistent with most experimental data (Table 4.1):
the ﬁve adjacent Asp's (D959-D963) in the core of Ca2+ bowl are reported as important for Ca2+ sen-
sitivity and/or binding [110] and in our model four of them (D959, D961, D962 and D963) coordinate
Ca2+. (ii) N949, N952 and Q954 are reported not to coordinate Ca2+ with their side chain oxygen
atoms [110, 111], this is fully consistent with our model. (iii) Q958 and Q972 do not bind Ca2+, which
is consistent with the results obtained in the study by Bao et al. [110]. (iv) In addition, the ﬁnding
that E946 and D957 bind Ca2+ is fully consistent with the data obtained by Sheng et al. [111], where
they have shown that single or combined mutations of E946A and D957A reduces Ca2+ sensitivity
and binding. However, it should be mentioned that it has been reported elsewhere [110] that both
Glu's present in the Ca2+ bowl are not important for Ca2+ binding, in contrast to the previous study.
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This issue therefore requires further studies. (v) The fact that D960 plays a role for Ca2+ sensitivity
and binding [110] may be also consistent with our model. Although in our structure, Ca5 is not
directly bound to D960, the negative electrostatic potential of the latter may play an important role
for stabilizing the ion in the close proximity of the protein.
The model is not consistent with some experimental data. Firstly, mutation of D950 to Ala does
not inﬂuence Ca2+ sensitivity or binding [111], yet in our model D950 binds Ca3. In addition, E967
should not bind Ca2+ [110], yet in our model it does bind Ca1. More reﬁned models could take these
pieces of information into account by performing constraint molecular dynamics simulations.
mutations experiment model model − 70ns
E946A no changes [110] reduces Ca2+ sensitivity
and binding (30%) [111]
does not bind Ca2+ Ca3 [1ox]
N949A no change [110] does not bind Ca2+ does not bind Ca2+
D950A no change [111] Ca3 [1ox]; Ca4 [1ox] Ca3 [1ox]
N952A no change [110, 111] Ca4 [bb ox] does not bind Ca2+
Q954A no change [110, 111] Ca5 [bb ox] does not bind Ca2+
D957A reduces Ca2+ sensitivity (50%) and Ca2+
binding (30%) [110, 111]
Ca3 [1ox]; Ca4 [1ox];
Ca5 [bb ox]
Ca3 [2ox]
Q958A reduces Ca2+ sensitivity (50%) and
binding ( 20%) [110]
does not bind Ca2+ does not bind Ca2+
D959A reduces Ca2+ sensitivity (60%); no data
for Ca2+ binding [110]
Ca1 [1ox]; Ca3 [bb
ox]
Ca1 [1ox]
D960A reduces Ca2+ sensitivity (90%) and
binding ( 50%) [110]
Ca5 [2ox] does not bind Ca2+
D961A no change in Ca2+ sensitivity; reduces
Ca2+ binding ( 50%) [110]
Ca1 [1ox]; Ca2 [1ox] Ca1 [2ox]
D962A reduces Ca2+ sensitivity (90%) and
binding ( 50%) [110]
Ca3 [1ox] Ca3 [2ox]
D963A reduces Ca2+ sensitivity ( 40%); no data
about binding [110]
Ca1 [1ox]; Ca2 [1ox] Ca1 [1ox,bb ox]
D965A reduces Ca2+ binding ( 30%) [110] Ca1 [bb ox] Ca1 [bb ox]
E967A no change [110] does not bind Ca2+ Ca1 [2ox]
Q972A reduces Ca2+ sensitivity ( 40%); no data
about binding [110]
does not bind Ca2+ does not bind Ca2+
E946A/D957A reduces Ca2+ sensitivity and binding
( 60%) [111]
D960A/D962A reduces Ca2+ binding ( 80%) [110]
D961A/D963A reduces Ca2+ binding ( 75%) [110]
K513D cause upward shift in the Ca2+ activation
proﬁle [97]
forms salt bridge
D546K cause upward shift in the Ca2+ activation
proﬁle [97]
forms salt bridge
K513D/D546K shift in the Ca2+ activation proﬁle similar
to that of WT [97]
forms salt bridge
Table 4.1: Available experimental data from which structural information can be extracted. In the
columns MODEL are presented results from homology models followed by the results of MD simula-
tions of Ca2+ binding to the Ca2+ bowl after 70 ns. Ca1-Ca5 identify position of the Ca2+ included
in the model and represent which Ca2+ binds to the determined residue; "bb ox" stands for backbone
oxygen.
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4.4 Concluding remarks
We have used biocomputing techniques to provide structural insights into the human big conductance
Ca2+- and voltage-gated K+ channel. We constructed a model of the RCK1 domain, which exhibits
the template Rossmann fold with two additional helices.
A model of the Ca2+ bowl was constructed based on the thrombospondin-1 T36 Ca2+-binding
domain and studied by MD simulations. Two well formed Ca2+-binding sites were identiﬁed that
explain most of the available experimental data data and can be helpful for planning future molecular
biology experiments in this pharmacologically relevant channels.
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Chapter 5
Regulation of Bestrophins by Ca2+
Abstract
Bestrophins are a recently discovered family of Cl− channels, for which no structural information is
available. Some family members are activated by increased intracellular Ca2+ concentration. Be-
strophins feature a well conserved Asp-rich tract in their COOH terminus (Asp-rich domain), which is
homologous to Ca2+-binding motifs in human thrombospondins and in human big-conductance Ca2+-
and voltage-gated K+ channels (BKCa). Consequently, the Asp-rich domain is also a candidate for
Ca2+ binding in bestrophins.
Based on these considerations, we constructed homology models of human bestrophin-1 (Best1)
Asp-rich domain using human thrombospondin-1 X-ray structure as a template. Molecular dynamics
simulations were used to identify Asp and Glu residues binding Ca2+ and to predict the eﬀects of their
mutations to alanine. We then proceeded to test selected mutations in the Asp-rich domain of the
highly homologous mouse bestrophin-2. The mutants expressed in HEK-293 cells were investigated
by electrophysiological experiments using the whole-cell voltage-clamp technique.
Based on our molecular modeling results, we predicted that Asp-rich domain has two deﬁned
binding sites and that D301A and D304A mutations may impact the binding of the metal ions. The
experiments conﬁrmed that these mutations do actually aﬀect the function of the protein causing a
large decrease in the Ca2+-activated Cl− current, fully consistent with our predictions. In addition,
other studied mutations (E306A, D312A) did not decrease Ca2+-activated Cl− current in agreement
with modeling results.
The experimental work was done in collaboration with the group of Prof. A. Menini at Neurobiology
sector of SISSA/ISAS: J. Rievaj, F. W. Grillo and A. Boccaccio. The computational work was done
in collaboration with C. Anselmi and F. Pietrucci (SISSA/ISAS).
5.1 Introduction
In 1998, the gene VMD2, which encodes for the human bestrophin-1 (hBest1) protein, was found to
be responsible for the inherited Best vitelliform macular dystrophy. This is an early-onset autosomal
dominant maculopathy typically characterized by yellowish lesions in the central area of the retina
[14, 15]. Since then, four human (hBest1-4) and three mouse (mBest1-3) genes were identiﬁed, together
with other genes from diﬀerent species (for review, see [16]). All human and mouse members of the
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bestrophin family have been expressed in heterologous systems [6, 112, 113, 114, 115]. The proteins
form Cl− channels, likely to be composed by several subunits [6, 116]. Three of them (hBest1, hBest4
and mBest2) are regulated by Ca2+ [6, 112, 23, 117]. They have been proposed as the putative
molecular counterpart of the Ca2+-activated Cl− current in some epithelial cells [118, 119, 120] and in
olfactory sensory neurons (mBest2), where they were suggested to play a pivotal role for the olfactory
transduction [117, 121, 122]. However, recent studies indicated that the TMEM16 family represents
a new candidate molecular counterpart of Ca2+-activated Cl− channels [123, 124, 125].
Although the link between the protein and the Best disease has not been clariﬁed yet [16, 126], it
has been established that more than one hundred mutations, mostly located in hydrophobic domains,
are associated with the disease [127, 128]. Some functionally highly relevant mutations (Q293K/H,
L294V, ∆I295, G299E/R, E300D, D301E, T307I and D312N) [16, 6, 17, 18, 19] are instead located at
the C-terminal domain inside the Asp-rich sequence from W287 to D323 (Asp-rich domain, hereafter).
These mutations reduce whole-cell currents compared to wild-type (WT) hBest1 after their expression
in heterologous systems [16, 6, 17, 18, 19]. Furthermore, inserting a stop codon in position L294 (but
not in position F353) causes a strong decrease of the current [129].
Clearly, knowledge of the structural determinants of the protein is crucial to understand its function
both in health and in disease conditions. However, no 3D structural information is available so far.
Nevertheless, two topology models have been proposed [114, 130]. According to them, the N- and
C-terminal domains of bestrophins would be located at the intracellular side of the membrane and
would be connected to four [130] or ﬁve [114] hydrophobic domains forming the channel.
In an eﬀort to characterize prominent structural and functional features of bestrophins, we noticed
that the Asp-rich domain, which has been indicated as a possible Ca2+ sensor for bestrophins [23]
is the most amenable region for molecular modeling studies. In fact, it has signiﬁcant sequence
similarity with other domains for which structural information is available. These include Ca2+-
binding domains as the cytoplasmic Ca2+ bowl motif [20, 131] of the big conductance Ca2+- and
voltage-gated K+ channels (BKCa) [20, 131, 132, 133, 21] and the type 3 (T3) motifs in the C-
terminal region of thrombospondins [134]. The ﬁrst corresponds to a highly conserved 28 amino acid
long peptide [20, 131] characterized by a net negative charge and ﬁve adjacent Asp's residues (D959-
D963 in human BKCa). Site-directed mutagenesis experiments have conﬁrmed the role of Ca2+ bowl
in the binding of calcium ions [21, 22]. Although the experimental 3D structure is not available, a
theoretical model of this domain in BKCa channels has been recently provided by us [135]. The model
turned out to be consistent with most of the available experimental data [21, 22].
The second type of Ca2+-binding domains, T3 repeats of thrombospondins, consists in tandems of
Asp-rich motifs [136], which resembles EF hands in the spacing of acidic side chains [137, 138]. The
X-ray structures of the C-terminal fragments of two human thrombospondins (TSP-1 and TSP-2)
show that they comprise several T3 motifs bound to as much as twenty six Ca2+ ions [136, 139].
Because of the signiﬁcant sequence similarity between the Asp-rich domain and the aforementioned
Ca2+-binding domains, it is plausible to hypothesize that Ca2+ activation of bestrophins could involve,
at least in part, Ca2+ binding to the Asp-rich domain. This hypothesis is fully consistent with the
experimental evidence from mutations of amino acids constituting putative Ca2+ ligands (E300D,
D301E and D312N) in the domain, which aﬀect dramatically the measured current in the HEK-293
cells [6, 18]. In addition, inserting a stop codon at position F353, located after the Asp-rich domain,
does not cause a current reduction, while cutting the channel at the ﬁrst amino acid in the Asp-rich
domain (L294) signiﬁcantly reduces the current [129]. Therefore we focused our attention on the
Asp-rich domain, whereas other possible Ca2+-binding domains were not explored here. On the other
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hand, computer simulations of the entire channel, which would help to clarify how Ca2+ binding could
aﬀect channel gating, are not feasible due to the lack of structural information of the transmembrane
region of the channel.
A straightforward approach to test if Asp-rich domain is involved in Ca2+ activation of be-
strophins+ would be to mutate randomly its Asp/Glu residues, that have the highest aﬃnity for
Ca2+, and then measure the functional properties of the channel. Here instead we followed a more
rational approach, which uses computation to guide the experiments. We ﬁrst constructed a structural
model of hBest1 Asp-rich domain based on the TSP-1 T36 X-ray structure [136], which has the largest
number of Ca2+-binding residues conserved across bestrophins. The models of WT and selected ala-
nine mutants were then studied by molecular simulations. Mutations with the largest predicted eﬀect
on Ca2+ binding turned out to cause a dramatic decrease in the experimentally measured mBest2
Ca2+-activated current (more than 96% reduction with respect to the WT mBest2). The consistency
between theory and experiments permits to have the ﬁrst structural insights on the hBest1 protein.
5.2 Computational details
5.2.1 Bioinformatics
The sequences of the human TSP-1 T35−7 repeats (PDB code: 1UX6) [136] were aligned with the
Ca2+ bowl from human and mouse BKCa channels [20, 131, 132, 133, 21, 140, 141] and the Asp-
rich domains of hBest1 [14, 15], mBest1 [15], hBest2 [142], mBest2 [143], hBest3 [142], mBest3 [144],
hBest4 [142], ceBest1 [6], dvBest1 [145], dmBest2 and dmBest4 [146] (Swiss-Prot entries and notations
are reported in the legend of Figure 5.2). The alignment was initially performed with ClustalW [47]
and then slightly reﬁned to avoid apolar residues in Ca2+ binding positions. Sequence similarity
was determined considering amino acid pairs having positive values in BLOSUM62 [147] substitution
matrices. The homology model of hBest1 Asp-rich domain from W287 to D323 was then built with the
MODELLER 6v2 program [4, 148], using the crystal structure of the TSP-1 T36 motif as a template
(PDB code: 1UX6) [136]. In the best resulting model, ﬁve to three Ca2+ ions present in the template
were kept. These are: (i) M5, with ﬁve Ca2+ ions coordinated. (ii) M4 is composed by four Ca2+ ions
which are Ca1, Ca2, Ca4and Ca5. (iii) M3' and M3 are including three Ca2+ ions, Ca1, Ca2, Ca4 or
Ca1, Ca2, Ca5, respectively.
5.2.2 MD simulations
Models of the Asp-rich domain were inserted in a box of edges 49, 50 and 53 Å ﬁlled with ~4,100
water molecules. Cl− (three in M5, one in M4) or Na+ (one in M3' and M3) counterions were added
to ensure systems charge neutrality. The force ﬁelds for the protein, ions and water molecules were
the Amber parm99 [149, 150] and TIP3P force ﬁelds, respectively [66].
For M5, energy minimization of water and counterions was performed with position restraints on
the Asp-rich domain and Ca2+ ions, with a force constant of value 25.0 kcal mol−1 Å−2. After the
ﬁrst 300 cycles of steepest descent minimization, conjugate gradient method was used until 50,000
cycles. Then steepest descent minimization of the system without restraints was performed for another
150 cycles, following by conjugate gradient minimization until 50,000 cycles. After that, constrained
solute and Ca2+ ions underwent 60 ps of linear heating MD from 0 K till 300 K. Restraints on Asp-rich
domain and Ca2+ ions corresponded to a force constant of 5.0 kcal mol−1 Å−2. A time step of 2 fs
was used.
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Finally, the system underwent NPT MD simulations for 75 ps at 1 fs time step. The system was
maintained at the reference pressure and temperature of 1 bar and 300 K, respectively, by coupling the
system to a Berendsen thermostat and barostat [102]. A cut-oﬀ of 9 Å was used for calculating non-
bonded interactions. Finally, unrestrained MD simulations were carried out for an overall length of
70 ns. A time step of 2 fs was used. All bond lengths were kept ﬁxed applying the LINCS algorithm
[151]. Temperature (300 K) and pressure (1 bar) were kept constant as aforementioned. Periodic
boundary conditions were applied treating long-range electrostatic interactions with the particle-mesh
Ewald technique using a short-range cutoﬀ of 10 Å [152]. The same cutoﬀ was used for the van der
Waals interactions. Pair lists were updated every 20 steps.
Models with four or three Ca2+ ions were built starting from the MD snapshot of M5 at 9 ns (after
the initial relaxation) by manually removing one or two ions (see above). In M4, M3' and M3 models
Ca3 was always removed since it is immediately solvated during the simulation of M5 (Figure 5.4).
M4, M3' and M3 underwent then MD simulations for 20 ns (M4) and 35 ns (M3', M3), respectively,
using exactly the same protocol as that used for the M5 model.
The models of the Asp-rich domain mutants (D301A, D302A, D303A, D304A, E306A, E306A+D323A,
D312A) were built, based on the M5 model, using the program Molden [153]. They underwent the
same protocol of minimization and relaxation of the WT followed by 20-ns MD runs.
The systems underwent minimization using Amber 8.0 program [154] and then MD simulations us-
ing the Gromacs 3.2.1 program [155, 156]. Trajectory analysis was performed by using the VMD 1.8.6
program [157].
5.2.3 Test of the accuracy of the force ﬁeld used in the MD simulations
The structures and energetics of Ca2+-binding proteins are diﬃcult to reproduce with current force
ﬁelds [158, 159]. Factors which limit the accuracy include the lack of polarizability and charge transfer
eﬀects [160]. Here we tested the accuracy of three force ﬁelds, the Aqvist [161], the Bradbrook [162]
and the AMBER one [163, 164]. We have performed 20-ns MD calculations of TSP-1 T36, for which
the X-ray structure is available [165], and compared crystal and MD structures. TSP-1 T36 is a 39
amino acids long loop resembling EF hands motif in the spacing of acidic side chains [166, 167]. It
binds ﬁve Ca2+ ions by eleven Asp and two Asn residues (Figure 5.1).
Figure 5.1: Crystal structure of the TSP-1 T36 domain. Five Ca2+ ions (indicated as Ca1−5 according
to their positions) are bonded to the Asp/Asn residues of the domain.
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Here we considered a structure in which all ﬁve (Ca1−5) calcium ions were present. The TSP-1 T36
domain was inserted in a box of edges 46, 51 and 49 Å ﬁlled with ∼ 3700 water molecules and 2 Cl−
counterions. Computational details for the relaxation and unrestrained MD simulation are the same
as reported in the section 5.2.2. In the three simulations, the ﬁnal structure turned out to be rather
similar to the X-ray structure: indeed the RMSD values calculated onto the N-terminal and C-terminal
halves were as small as 3.2 Å and 2.4 Å, respectively (Table 5.1) and Ca1−4(Figure 5.1) remained
bound. However, the total backbone RMSD from the X-ray structure was relatively large (Table 5.1)
because of conformational changes of Ca5-binding groups (D880 and D887); in fact, Ca5 was solvated
after few ns ( ∼ 2 ns for Aqvist- and Bradbrook-based MD; ∼ 1.3 ns for the AMBER-based MD).
Aqvist [161] Bradbrook [162] AMBER [163, 164]
Total RMSD 3.5 5.2 5.5
RMSD of N-term 3.5 3.8 3.2
RMSD of C-term 2.6 4.3 2.4
Table 5.1: TSP-1 T36 backbone RMSD values (Å) relative to the X-ray structure after 20-ns MD
simulations based on three diﬀerent force ﬁelds. The N-term corresponds to the residues from A865
to H878, whereas the C-term corresponds to the residues from D879 to N897 (see also 5.2).
The loss of the Ca2+ ion might be caused by several factors, including the limitations of the
accuracy of the force ﬁeld describing the Ca2+ ions [159] and/or the absence of electrostatic packing
forces in the simulation with respect to the crystal, along with a diﬀerence in temperature (the
simulation was run at 300 K, the crystal structure was solved at 100 K). Force-matching methods,
which were applied by us already for other metal-containing systems [168], might be used to further
address this issue, which is however beyond the scope of this study. Because of the limitations of the
approach used in our structural predictions, we used our molecular modeling only to identify alanine
mutations in Asp-rich domain which may play a role for the Ca2+ binding. No attempts were made
to use our computations to predict the structure of disease-linked mutants [169] and/or mutants for
which electrophysiological experiments have been previously carried out [170]. In all of the other
calculations presented here we have used the AMBER force ﬁeld.
5.2.4 Metadynamics
A 60-ns long metadynamics simulation was performed by biasing two collective variables (CVs) with
a history-dependent potential. These are the coordination numbers of Ca2 and Ca4 to Asp and Glu
residues of the Asp-rich domain. They were deﬁned as the number of contacts shorter than 4.3 Å
among one Ca2+ ion and all carboxylate carbons of the studied domain:
Si =
∑
j
nij , nij =
1−
(
Rij
R0
)8
1−
(
Rij
R0
)16
where i runs over Ca2 and Ca4, j runs over all carboxylate carbons, Rij is the distance between the
two atoms, R0 = 4.3 Å is a cutoﬀ distance chosen in order to discriminate between bonded and non-
bonded Ca2+ ions (this cutoﬀ distance ensures that Ca2+ ion is considered bonded when it is at most
3 Å away from carboxylate oxygen atoms (see e.g. [171]), and nij is a function switching smoothly
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between 1 (bonded Ca2+ ion) and 0 (non-bonded Ca2+ ion). Similar CVs have been employed in a
previous study of Ca2+-binding polymers [172]. The 2-D Gaussians forming the metadynamics bias
potential have width σ1 = σ2 = 0.2 (along S1 and S2 respectively) and a height of 0.2 kcal/mol. A new
Gaussian is added along the trajectory every 1 ps. Metadynamics [173] is implemented in a modiﬁed
version of the Gromacs 3.3.1 package [156].
5.2.5 Experimental studies
5.2.5.1 Site-speciﬁc mutations of mBest2 and heterologous expression
The clone of mBest2 in pCMV-Sport6 mammalian expression plasmid was obtained from the RZPD
(Berlin, Germany) collection (Deutsches Ressourcenzentrum für Genomforschung). Site-speciﬁc mu-
tations of mBest2 were made using a PCR-based site-directed mutagenesis kit (Quiagen). Mutations
were conﬁrmed by DNA sequencing.
mBest2 and its mutants were transfected into HEK-293 cells along with a vector that expressed
EGFP (pEGFP; Invitrogen) at a 1:8 ratio using Fugene-6 transfection reagent (Roche). 2 days after
transfection, cells were dissociated and replated. Transfected cells were identiﬁed by EGFP ﬂuores-
cence and used for patch clamp experiments within 3 days after transfection.
5.2.5.2 Immunoﬂuorescence and confocal microscopy
To test successful expression of proteins, as well as their spatial distribution in HEK-293 cells, we used
co-staining of antibodies against mBest2 and labeled wheat germ agglutinin (WGA) as a marker of
glycosylated surface-expressed proteins - a method previously used to show localization of proteins in
cell membrane and/or close submembrane space [174, 175].
Transfected cells (without the EGFP expressing vector) were ﬁxed with 4% paraphormaldehyde
for 20 min, washed, incubated with 5 µg/ml WGA conjugated to Alexa Fluor 488 (Invitrogen) for
20-30 min, incubated for 30 min in blocking solution containing 1% BSA (Sigma), 0.1% Triton X-100
(Sigma) and 1% FCS (Sigma), then for 2 hours with an antibody against mBest2 [117] (diluted in
1:500 ratio with blocking solution), washed extensively and incubated with a A594-conjugated anti-
rabbit secondary antibody (Invitrogen, diluted 1:500 in blocking solution) for 1 hour, washed and
mounted with Vectashield (Vector Laboratories, Burlingame, CA). Immunoreactivity was analyzed
by confocal microscopy with a Leica TCS SP2 confocal microscope. All incubations were made at
room temperature; all substances were diluted in PBS, unless otherwise indicated.
5.2.5.3 Electrophysiological recordings
Currents were measured with an Axopatch 200B patch-clamp ampliﬁer (Molecular Devices, CA, USA)
in the whole-cell voltage-clamp mode. The ampliﬁer was controlled via a Digidata 1440A (Molecular
Devices, CA, USA).
Patch pipettes were made using borosilicate capillaries (WPI, Sarasota, Florida, USA) and pulled
with a Narishige PP83 puller (Narishige, Tokyo, Japan), using a double stage pull. The pipette
resistance was 2-4 MΩ. Data were sampled at 20 kHz and low-pass ﬁltered at 10 kHz. Acquisition
and storage of data were performed with the PClamp 10 software (Axon Instruments, CA, USA).
Data analysis and ﬁgures were made with the Clampﬁt 10 software (Axon Instruments, CA, USA)
and Igor 6.0 software (Wavemetrics, Lake Oswego, OR, USA).
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The holding potential was 0 mV and a voltage protocol from -100 mV to +100 mV, with 20 mV
steps of 200 ms duration was applied (starting 2 minutes after reaching the whole-cell conﬁguration).
Cell capacitance was estimated from a 10 mV step test protocol in the presence of the extracellular Cl−
current blocker SITS. Current densities were calculated normalizing the current recorded at +60 mV
to the capacitance of each cell. Data are shown as mean ± standard error of the mean. N is the
number of cells. Statistical signiﬁcance was determined using un-paired t-tests. P values <0.05 were
considered signiﬁcant.
The standard extracellular solution contained (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2,
and 10 HEPES, 10 Glucose, pH=7.4. The pipette solution contained (in mM): 130 CsCl, 2 MgCl2,
10 HEPES, 5 EGTA without added Ca2+ for the nominally 0 Ca2+ solution, or with 5 mM CaCl2
for the 22 µM Ca2+ free pipette solutions (free Ca2+ was calculated with the program WinMAXC, C.
Patton, Stanford University, Palo Alto, CA, USA). pH was adjusted to 7.3 by adding HCl or CsOH.
The osmolarity was adjusted with sucrose to 310 or 300 mOsm for the extracellular and intracellular
solution, respectively.
To block Cl− currents, the extracellular blocker 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate
(SITS) was directly dissolved in the extracellular solution at 2 mM. All chemicals were purchased from
Sigma. All experiments were carried out at room temperature (20-22°C).
5.3 Results
Our strategy to identify Asp and Glu amino acids important for the function of hBest1 was twofold.
First, we attempted to identify residues that may bind the Ca2+ ions in the WT. Next, we predicted
the eﬀects of mutations to alanine of these residues on the structure and function of the Asp-rich
domain. The eﬀect is non-trivial, because residues, which bind Ca2+ ions in the WT, can be replaced
by others when mutated to alanine.
5.3.1 Identiﬁcation of acidic residues binding Ca2+ in hBest1 Asp-rich do-
main
The structural determinants of the Asp-rich domain were modeled by using the X-ray structure of
TSP-1 T36 repeat [136] as a template, because it exhibits the largest number of Ca2+-binding residues
conserved across bestrophins family (Figure 5.2).
The number of Ca2+ ions bound to the Asp-rich domain is unknown. Typically, as observed from
other Ca2+-binding domains in the PDB database, each Ca2+ ion is usually coordinated by three
Asp/Glu residues [171]. Since the template has ﬁve Ca2+ ions bound and 33% of negatively charged
residues more than the Asp-rich domain, it is plausible to expect that the last would bind ﬁve or less
Ca2+ ions. Therefore we considered models including ﬁve (M5), four (M4), and three (M3', M3)
Ca2+ ions (Figure 5.3).
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Figure 5.2: Alignment of the Asp-rich sequences from TSP-1, BKCa and bestrophins. Alignment
between TSP-1 T35−7 repeats [136], human BKCa Ca2+ bowl (SwissProt entry: Q12791) [133],
mouse BKCa Ca2+ bowl (SwissProt entry: Q08460) [132] and the Asp-rich domain at the C-terminal
part of hBest1 (SwissProt entry: O76090) [14, 15]. hBest1 shares in this tract 33% to 36% of
sequence similarity with TSP-1 T35−7 motifs and 42% with BKCa Ca2+ bowl [21]. Bold letters
represent residues, which are involved in Ca2+ binding in TSP-1 (as found in the crystal struc-
ture (1) [136]), hBKCa and mBKCa (from the model (2) described in section 4.3.3) and hBest1
(this work (3)). O-donor residues are colored in red (negatively charged residues) or green (neutral
residues). The alignments of selected tracts from the C-terminal domains of other bestrophins are
also shown: mBest1 (mouse bestrophin-1, SwissProt entry: O88870), hBest2 (human bestrophin-
2, SwissProt entry: Q8NFU1), mBest2 (mouse bestrophin-2, SwissProt entry: Q8BGM5), hBest3
(human bestrophin-3, SwissProt entry: Q8N1M1), mBest3 (mouse bestrophin-3, SwissProt entry:
Q6H1V1), hBest4 (human bestrophin-4, SwissProt entry: Q8NFU0), ceBest1 (Caenorhabditis elegans
bestrophin-1, SwissProt entry: Q21973), dvBest1 (Drosophila virilis bestrophin-1, SwissProt entry:
Q20C62), dmBest2 (Drosophila melanogaster bestrophin-2, SwissProt entry: Q9VRW4), dmBest4
(Drosophila melanogaster bestrophin-4, SwissProt entry: Q9VUM6).
Figure 5.3: Initial model of the Asp-rich domain studied by the MD simulations. The Ca2+ ions
and the residues coordinating them are shown as sphere and licorice, respectively. M5 comprises ﬁve
Ca2+ ions, labeled for clarity as Ca1−5 according to their binding positions (The same labels are used
throughout the text). M4 is the same as M5 except that it lacks Ca3 (colored in blue). M3' and M3
are the same as M4 except that they lack Ca5 (green), and Ca4 (magenta), respectively.
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In all molecular dynamics (MD) simulations, two ions (Ca1 and Ca2 in Figure 5.4) remained bound.
Ca1 was bound to D302, D304, E306 and D312, Ca2 to D303, D304, E306, D312, Q316, S318 and
D323 (Table 5.2).
Instead, the other ions were partially or completely solvated. The decrease in the number of bound
Ca2+ ions with respect to TSP-1 T36 can be caused by a combination of factors: ﬁrst of all, the lower
number of negatively charged residues in Asp-rich domain with respect to T36 (C-type repeat is well
conserved in hBest1, while N-type is not; Figure 5.2), but also the limitations associated with the
force ﬁeld (see section 5.2.3). MD simulations showed that residues D302, D304, E306, D312 and
D323 (Table 5.2) play a major role for Ca2+ binding.
In order to identify other Ca2+-binding residues, we used an enhanced sampling method, i.e. meta-
dynamics [33]. In this approach, the MD simulation is altered by biasing the selected collective vari-
ables (CVs) with a history-dependent potential. The bias, constructed as a sum of Gaussians centered
along the trajectory of the system, reduces the free-energy barriers and enhances the rate of tran-
sitions, in the present case the binding and unbinding of Ca2+ ions. The starting structure for the
metadynamics simulation was selected among our energy-minimized models. We chose M3' model,
because it kept the largest number of bound Ca2+ ions (three) during the MD simulations for as long
as 25 ns (Figure 5.4).
Ca1 Ca2 Ca4 Ca5
Glu292 56%
Asn296 41%
Glu300 100%
Asp302 100%
Asp303 31% 63% 88%
Asp304 100% 100%
Asp304 (bb) 71% -
Glu306 100% 93% 87%
Asp312 100% 36% 71%
Asp312 (bb) - - 50%
Gln316 25%
Ser318 44%
Ser318 (bb) 73%
Asp323 100%
Table 5.2: Percentage of time during which speciﬁc residue binds Ca2+ ions. Percentages were averaged
over all MD simulations of all the studied models. Ca3 is not reported as it is never bound to the
protein. bb indicates that the backbone carbonyl oxygen is involved in the binding.
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The selected CVs measured the extent of binding of Ca2 and Ca4, respectively, since Ca1 was
always bound to a well-deﬁned binding pocket in all previous simulations. The limitations of the force
ﬁeld along with the large number of conformational degrees of freedom of the system prevented us
from calculating the free-energy proﬁle associated to Ca2+ binding. Therefore, the simulation was
only used to sample stable conﬁgurations, diﬀerent from those studied in the MD.
Figure 5.5: Metadynamics simulation of M3' model. -A: Number of peptide O-donors (red) and water
molecules (blue) coordinating Ca1 through the metadynamics simulations of the Asp-rich domain of
hBest1. As in standard MD, Ca1 is stably bound to the protein for most of the time. B: Number of
peptide O-donors coordinating Ca2 (black) and Ca4 (green) plotted as a function of the metadynamics
simulation time.
Throughout the metadynamics run, Ca1 kept its coordination shell as in the previous MD simula-
tions (Table 5.2 and Figure 5.5A). Due to the bias potential, Ca2 and Ca4 instead turned out to bind
and unbind several times (Figure 5.5B) exploring diﬀerent conﬁgurations.
Ca2 was either bound to D301, D302, D303, D312 and D323 (Figure 5.6) or it was solvated. Analo-
gously, the third Ca2+ ion (Ca4 in Figure 5.6) was bound to D301, D302, D303, D304, E306, D312 and
D323 in some of the stable conformations. Therefore, our metadynamics simulations conﬁrmed that
the residues identiﬁed by MD can play a role for Ca2+ binding. In addition, they further suggested a
possible role of D301 and D303 for such binding.
Figure 5.6: Metadynamics simulations of M3' model. Pictorial representation of the most populated
structures with one, two or three coordinated Ca2+ ions emerging from the simulations. Notice that
Ca1 binding pocket formed by D302, D304, E306 and D312 is always occupied. In addition, the second
Ca2+ ion always occupies Ca2 binding pocket.
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Figure 5.4: MD simulations of M3'-M5 models. Ca2+ coordination numbers contributed by protein
O-donors (red) and water molecules (blue) plotted as a function of simulation time. Ca2+ ions were
deﬁned as stably bound if their coordination number was at least 6 and not more than 2 water
molecules contributed to their binding.
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5.3.2 Computer-aided design of mutants with low-aﬃnity for Ca2+
We attempted to identify mutations that could have an eﬀect on Ca2+ binding. We constructed
structural models in which putative key Asp and Glu residues among those identiﬁed in the above
section were mutated to alanine. These are D301A, D302A, D303A, D304A, E306A, D312A and the
double mutant E306A+D323A (see Table 5.3). Adducts with ﬁve Ca2+ ions underwent 20 ns of MD.
At the end of MD simulations, D301A bound only one Ca2+ ion (Table 5.3), while its 3-D structure
remained similar to that of WT.
The Asp-rich domain bearing D304A mutation unfolded, possibly because D304 is the central
residue of the domain and therefore responsible for its structural stability; all Ca2+ ions were partially
or fully solvated (Table 5.3). Since the structural information of the channel is lacking, it is diﬃcult
to establish if unfolding of D304A would occur also in the real molecular surrounding, that is, when
the Asp-rich domain is attached to the remaining bestrophin part.
Mutants D302A, D303A, E306A, and D312A resembled the WT as they bound at least two Ca2+
ions (Table 5.3). In fact, other residues contributed to Ca2+ coordination replacing the mutated ones.
Based on these results we concluded that D301A and D304A mutations have the largest eﬀect
on Ca2+ binding, while D302A, D303A, E306A, and D312A aﬀect Ca2+ binding to a lesser extent.
To verify this, the experiments of the WT and mutant mBest2 were performed. The putative Ca2+-
binding domain of mBest2 has almost the same sequence as that of hBest1 (Figure 5.2). To investigate
whether the WT structures are aﬀected by the diﬀerences, MD simulations were performed also on
mBest2. As a result of MD simulations both models showed very similar behavior, with Ca1 and Ca2
that remained stably bound, while Ca3 and Ca5 were solvated. Ca4 bound more peptide O-donors
in mBest2 than in hBest1. However, this diﬀerence should not be overestimated, since even starting
from the same initial system (e.g. hBest1), running two independent MD simulations of the same
length could result in slightly diﬀerent events.
Ca1 Ca2 Ca3 Ca4 Ca5 EXP
WT (0 ns) 6+0 6+1 4+4 6+1 5+2 -
WT (20 ns) 6+1 7+1 5+3 4+3 5+3 -
D301A 5+3 5+2 5+3 5+3 3+4 no current
D302A 6+2 6+2 2+4 5+3 2+6 -
D303A 7+1 7+1 3+5 5+3 2+6 -
D304A 4+4 5+3 0+8 3+5 2+6 no current
E306A 6+1 8+0 4+4 6+1 4+4 current
D312A 6+2 7+1 2+4 4+4 0+7 current
Table 5.3: MD simulations of the M3' model and its alanine mutants. Ca2+ protein coordination
numbers in WT and the investigated mutants of the Asp-rich domain, as observed after 20 ns of MD
simulations. First number refers to the number of peptide O-donors, whereas the second refers to the
number of coordinated waters. Ca2+ ions were considered bound if they were coordinated with at
least 5 protein O-donors and not more than 2 water molecules. Bound ions are highlighted.
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5.3.3 Experimental studies
5.3.3.1 Current recordings of wild-type and designed mutants
The changes of Ca2+ coordination in the aforementioned mutations may aﬀect the amplitude of
bestrophin Ca2+-activated Cl− currents, which can be experimentally measured. This was done here
for mouse bestrophin2 (mBest2). WT and mutants currents were compared after their heterologous
expression in the HEK-293 cell line (Figure 5.7).
To determine if mutant proteins are delivered to the plasma membrane as WT, we used immunos-
taining with antibodies against mBest2 [117]. The WT protein showed increased localization in plasma
membrane and/or in close sub-membrane space in a signiﬁcant portion of transfected cells, although
some fraction of protein was localized also intracellulary (Figure 5.7A). These results are similar to
data previously published for hBest2 [115] and xBest2 [174]. The localization of the proteins was fur-
ther investigated by co-staining with ﬂuorescently labeled wheat germ agglutinin (WGA), a selective
marker of glycosylated surface-expressed proteins. Co-localization of both signals, which indicates
membrane expression of the protein, was observed. The distribution of mBest2-related signal and its
co-localization with WGA in mutants were very similar to WT, indicating that the proteins were ex-
pressed and delivered to the plasma membrane (Figure 5.7). Consequently, changes of the measured
current were caused by a modiﬁcation of the channel functionality and not by the inability of the
mutant proteins to reach the plasma membrane.
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Figure 5.7: Localization of mBest2 and its mutants in HEK-293 cells. mBest2 was transfected into
HEK-293 cells. 2-4 days after transfection, the cells were ﬁxed, permeabilized and stained with
antibody against mBest2, then visualized with Alexa-594-conjugated secondary antibody. Cells were
also stained with Alexa-488 conjugated wheat germ agglutinin (WGA). Typical cell transfected with
wild type mBest2 is shown in (A). Signal from mBest2 staining (red) is shown in the left, signal
from WGA (green) from the same cell is in the middle. Overlay of both signals (right) indicates the
expression of protein in plasma membrane and/or in close submembrane space. The distribution of
mBest2 at the membrane was determined by comparing red and green ﬂuorescence along a line drawn
across a cell. Distribution of WGA- and mBest2- associated ﬂuorescence along the line across the
cell is shown in (B), line is shown in (C). Similar procedure was repeated for all ﬁve investigated
mutations. Results for wild type (WT) mBest2, D301A, D304A, E306A, D304A+E306A and D312A
mutations are compared in (D). Signal from staining against mBest2 (red) is shown in ﬁrst row,
signal from WGA (green) in the middle, overlay of both signals is in third row. Cells transfected with
all investigated mutations showed similar distribution of signals, conﬁrming increased localization of
mutated proteins in plasma membrane and/or in close submembrane space. Non-transfected cells had
negligible mBest2-associated ﬂuorescence (data not shown).
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We then measured currents in HEK-293 cells transfected with mBest2 WT or mutants both in
nominally 0 free Ca2+ level and in 22 µM free Ca2+ intracellular concentration. Currents were
measured in the whole-cell voltage-clamp conﬁguration applying voltage-steps of 20 mV from -100 mV
to +100 mV from a holding potential of 0 mV. The current values at +60 mV were normalized to the
capacitance of each cell and averaged.
The WT current in nominally 0 Ca2+ was signiﬁcantly smaller than that in 22 µM Ca2+ concen-
tration (Figures 5.8-5.9).
Figure 5.8: Currents in HEK-293 transfected cells. Currents in HEK-293 cells transfected with EGFP
and WT mBest2 (left column) or D304A mutant (right column). Transfected cells were identiﬁed
by the EGFP-expressed green ﬂuorescence. Whole-cell voltage clamp recordings were obtained with
pipette solutions containing nominally 0 (A) or 22 µM free Ca2+ (B-D). For each type of channel,
recordings in B-D were obtained from the same cell, while traces in A are from diﬀerent cells. Voltage
steps of 200 ms duration were given 2 min after the reaching of the whole-cell conﬁguration from a
holding potential of 0 mV to voltages between -100 and + 100 mV in 20 mV steps. In the left column,
panels C and D show the reversible block of the WT current by 2 mM SITS, a Cl− channel blocker.
The mutant D304A did not show an appreciable current when Ca2+ was present in the intracellular
solution (right column; see also Figure 5.9).
This shows that Ca2+ ions activated a current in agreement with previous results [112, 117]. Most
of the Ca2+-induced current was reversibly blocked by the Cl− channel blocker SITS indicating the
current is indeed carried by Cl−. In contrast, D304A and D301A produced negligibly small currents in
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both Ca2+ levels (Figure 5.9). Two other mutants, E306A and D312A, produced currents: whilst the
amplitude of the current of E306A was similar to that of WT (Figure 5.9), D312A showed a somehow
unexpected result. It produced a substantial amount of current in the nominally 0 Ca2+ concentration
(Figure 5.9). In 22 µM Ca2+ concentration, the current signiﬁcantly increased and was larger than
that of WT. The current was also blocked by SITS in both Ca2+ levels, indicating that it is a Cl−
current (data not shown). Therefore, the D312A mutation not only allowed a Ca2+-activated Cl−
current, but it also modiﬁed channel gating increasing its current also in the absence of Ca2+. Finally,
the double mutant D304A+E306A abolished the current, similarly to the single mutant D304A (Figure
5.9).
Figure 5.9: Comparison of current amplitudes from mutant and WT mBest2 Cl− channels. Mean
current densities from non-transfected cells (HEK nt) and cells transfected with EGFP and WT or
mutated mBest2. The intracellular pipette solution contained nominally 0 (white bar) or 22 µM free
Ca2+ (black bar). Data are shown as mean values ± standard error of the mean. Each data represents
the mean of at least ﬁve cells. Control experiments with non-transfected HEK-293 cells did not show
any appreciable current. Mean current densities in the presence of 22 µM free Ca2+ of WT, E306A and
D312A were signiﬁcantly higher than those in nominally 0 Ca2+ (P<0.02; N=5-8), whereas currents
at the two Ca2+ levels were not statistically diﬀerent for D301A, D304A and D304A+E306A (P>0.05,
N=5-20). Currents in the presence of 22 µM free Ca2+ of D301A, D304A, and D304A+E306A were
substantially decreased compared with WT (P<0.002 for each group, N=5-20). E306A had a mean
value not signiﬁcantly diﬀerent fromWT (P=0.5; N=7-8). D312A showed a current increase compared
to WT both in the absence (P=0.03; N=6-8) and in the presence of Ca2+ (P=0.003; N=6-9).
Experiments showed that WT, E306A and D312A mutants allowed a substantial Ca2+-activated
current, whereas D301A and D304A mutants produced a negligibly small Ca2+-activated current.
These results were fully consistent with our theoretical predictions.
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5.3.4 Concluding remarks
Understanding the interactions between the Ca2+ ions and the Asp-rich domain in bestrophins is
an important step in the investigation of the physiological role of these proteins, because they are
putatively involved in the Ca2+-activated Cl− current in some epithelial cells [118, 119, 120]. In
addition, it seems to be also important for understanding the pathophysiology of the Best disease,
since the Asp-rich domain is a hot spot for mutations causing the illness [127, 128]. At present
nothing is known about the underlying structural features of the bestrophins.
We propose that the Asp-rich domain located at the C-terminal region of bestrophins can con-
tribute to Ca2+ binding [23], due to its similarity with other Ca2+-binding domains, as the Ca2+ bowl
in BKCa [20, 21, 22] and T3 repeats of thrombospondins [134, 136, 139]. This statement is consistent
with previous experimental data, which show that mutations of putative Ca2+ ligands in bestrophin
Asp-rich domain aﬀect dramatically the current [6, 18].
In order to identify negatively charged residues in the domain involved in Ca2+ binding, we adopted
a multifaceted strategy involving homology modeling, MD simulations, immunostaining and electro-
physiological experiments of WT and mutated bestrophins.
Theoretical data suggest that not all Asp and Glu residues have equal importance in Ca2+ binding.
Simulations of D301A and D304A mutants show that they are crucial for the capacity of the domain to
bind Ca2+. Measures of Ca2+-sensitive Cl− current of WT and mutant bestrophins expressed in HEK-
293 cells show that D301A and D304A mutations do actually aﬀect the functionality of the channel,
dramatically reducing the Ca2+-activated current amplitude. These ﬁndings are fully consistent with
our theoretical predictions.
Other residues, E306 and D312 bind Ca2+ in the MD simulations. In our experiments, the mutation
of these residues to alanine does not cause reduction in the current in agreement with the simulations,
since other O-donors replace the aforesaid residues in the Ca2+ coordination shell.
In conclusion, simulations suggest that at least two Ca2+-binding sites could be present in the
Asp-rich domain of bestrophins. Furthermore, electrophysiological experiments show that mutations
predicted by our modeling have an impact on the function, decreasing the Ca2+-activated current
amplitude and conﬁrming the importance of the bestrophin Asp-rich domain in Ca2+- dependent
activation of the channel.
Finally, the presence of Asp repeats also in thrombospondins and BKCa channels suggests that
they could represent a general motif for Ca2+ binding in diﬀerent classes of proteins.
5.3.4.1 Results of a recently published study by Xiao et al.
After the submission of this work for publication, a paper by Xiao et al. [176] has been published
discussing the role of Ca2+ regulation in human bestrophin-1 (hBest1). They conﬁrmed direct binding
of Ca2+ to hBest1 Asp-rich domain by the autoradiography of the blot containing hBest1 C-terminus
after its exposure to the 45Ca2+. They studied diﬀerent point mutations for each residue in the
Asp-rich domain by measuring the currents after overexpression of the mutated proteins in HEK cells.
Based on the experimental results, they constructed a homology model of the Asp-rich domain
using the third EF hand domain of human calmodulin (CaM, PDB code: 1CLL, [177]) as a tem-
plate. They suggested one Ca2+-binding site formed by the residues D312, N314, Q316, S318 and
D323. However, they measured a reduced current only for D312 and D323, while the other residues
were considered by analogy to the general EF-hand motif. In agreement with our simulations, they
pointed out the role of D312 and D323 for Ca2+ binding. However, they did very limited theoretical
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investigation: they estimated free energy of Ca2+ binding to a single conﬁguration of WT and D312G
mutant by implicit solvent Poisson-Boltzmann calculation. The results were not cross-checked by MD
simulations in explicit solvent which is crucial for metal-ions based proteins.
Part III
Prion protein
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Chapter 6
D18 scFv fragment in prion diseases
therapy
Abstract
Prion is infectious protein responsible for a group of fatal neurodegenerative diseases called transmissi-
ble spongiform encephalopathies (TSEs), or prion diseases. In mammals, prions reproduce themselves
by recruiting the normal cellular protein (PrPC) and inducing its conversion to the disease-causing
isoform denominated PrPSc. Recently, anti-prion antibodies have been shown to permanently cure
prion-infected cells. However, the inability of full-length antibodies and proteins to cross the blood
brain barrier (BBB) hampers their use in the therapy of TSEs in vivo. Alternatively, brain delivery of
prion-speciﬁc single-chain variable fragment (scFv) by adeno-associated virus (AAV) transfer delays
the onset of the disease in infected mice, although protection is not complete. We investigated the
anti-prion eﬀects of a recombinant anti-PrP (D18) scFv by direct addition to scrapie infected cell cul-
tures or by infection with both lentivirus and adeno-associated virus (AAV) transducing vectors. We
show that recombinant anti-PrP scFv is able to reduce PrPSc content in infected cells. In addition,
we demonstrate that lentiviruses are more eﬃcient than AAV in gene transferring of the anti-PrP
scFv gene and in reducing PrPSc content in infected neuronal cell lines. Finally, we have used a
bioinformatics approach to construct a structural model of D18scFv-PrPC complex. Interestingly,
according to the docking results, ArgPrP151 (Arg151 from prion protein) is the key residue for the
interactions with D18scFv, anchoring the PrPC to the cavity of the antibody. Taken together, these
results indicate that combined passive and active immunotherapy targeting PrP might be promising
strategies for therapeutic intervention in prion diseases.
The experimental work was carried out by V. Campana, P. Casanova and Prof. C. Zurzolo at
the Unité de Traﬁc Membranaire et Pathogénèse, Institut Pasteur, Paris, France; by L. Zentilin and
M. Giacca at the International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste,
Italy; by I. Mirabile and Prof. G. Legname at the Neurobiology sector of SISSA and by Prof. S. B.
Prusiner from the Institute for Neurodegenerative Diseases, University of California San Francisco,
U.S.A.
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6.1 Introduction
Transmissible spongiform encephalopathies (TSEs) or prion diseases are fatal neurodegenerative disor-
ders that aﬀects humans and animals. The etiology of these pathologies can be infectious (like bovine
spongiform encephalopathy or new variant Creutzfeldt-Jakob disease), sporadic or genetic. Industrial
cannibalism has been responsible for one of the most infamous TSE epidemics, bovine spongiform
encephalopathy (BSE), paralleled with an increasing number of human cases with a variant form of
Creutzfeldt-Jakob disease from BSE-contaminated beef products [178]. All of TSEs are caused by a
prion or PrPSc which is a conformational isoform of the cellular prion protein PrPC [179].
PrPC is a α-helical monomeric protein (Figure 6.1). The fold consists of a structured and an
unstructured part [180]. The structured part consists of three α helices (residues D144-R156, N173-
K194 and E200-Q227) and two β strands (residues M129-A133 and Q160-Y163) (PDB code: 1HJM
[180]). The unstructured part consists of ﬁrst 124 residues. Its structural features could not be
determined so far.
Figure 6.1: NMR structure of human PrPC at pH=7. The dotted line represents the unstructured
N-terminal part.
PrPC is normally expressed in mammals, although its physiological role is not yet fully understood.
It has been proposed to be involved in copper and/or zinc transport or metabolism [181, 182, 183],
protection from oxidative stress [183], cellular signaling [184, 185], membrane excitability and synaptic
transmission [186, 187], neuritogenesis [188] and apoptosis [184, 189]. In contrast, PrPSc is composed
mostly by β-strands [179], and is therefore able to aggregate. In addition, it is partially resistant to the
degradation by the proteases [179]. All these features concurrently result in a substantial diﬀerence, i.e.
PrPSc is infectious, whereas PrPC is not. The key element in pathogenesis of prion diseases is a direct
interaction between the pathologic PrPSc and the endogenous PrPC and the following conformational
conversion of PrPC into PrPSc. Conversion can be assisted with yet-unknown molecular chaperon
(chaperon X) [190, 191]. PrPSc then agregates and forms ﬁbrils that are deposited in neurons what
leads to the neurodegeneration and rapid death [192].
Over the past years, many anti-prion compounds have been identiﬁed in in vitro models of prion
replication, such as polysulphated polyanionic compounds, polyamine, tetrapyrroles, polyene antibi-
otics, peptides, tetracyclic and tryciclic compounds (reviewed in [193]). However most of these
molecules were found to be toxic or ineﬀective in animal models of prion diseases (reviewed in
[194, 195, 193]).
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Alternatively, anti-prion protein antibodies have been shown to have an antiprion eﬀect in cellular
and animal models [28, 196, 197, 198]. Diﬀerent publications report that antibodies directed against
the middle portion of PrP (residues 91-110 and 132-156) can cure scrapie infected cells in culture
and reduce PrPSc in spleens of infected mice (reviewed in [28, 196, 199]). Despite these encouraging
results, development of eﬀective immunotherapy presents several problems both in active and passive
approaches. An important obstacle in the development of eﬃcacious regimens for active immuniza-
tion is host tolerance to endogenous PrPC , which limited the therapeutic eﬃcacy of this immunization
approach [198, 200]. In comparison, passive immunization suﬀers from the intrinsic problem of poor
antibody diﬀusion from vessels into tissues, especially in the nervous tissue: administration of mon-
oclonal antibodies has been shown to prevent the pathogenesis only when applied simultaneously, or
shortly after, peripheral prion infection [199]. Moreover, production of large amounts of monoclonal
antibodies for therapy is technically challenging and expensive.
In 2001, Peretz and co-workers [28] analyzed the ability of some recombinant antibody antigen-
binding fragments (Fabs; see Section 6.1.1) to inhibit prion propagation in a cultured mouse neu-
roblastoma cell line infected with PrPSc. The most eﬀective Fab, D18, was found to abolish prion
replication and to clear pre-exiting PrPSc, eliminating 50% of PrPSc from the cells within about 24
hours. The activity of D18 was attributed to its ability to speciﬁcally recognize the total population of
PrPC molecules on the cell surface. In PrPC , D18 epitope spans from residues 132-156 and incorpo-
rates helix A. This sequence lays within the region of the protein thought to bind PrPSc, an essential
step for prion propagation: therefore, it can be argued that D18 operates mechanistically by directly
blocking or modifying interaction of PrPC with PrPSc [28]. Compared to full-length antibodies, Fabs
are smaller molecules but their transport via blood-brain barrier in vivo is still negligible. A promising
solution to this problem is oﬀered by the use of single chain variable fragments or scFv (see Section
6.1.1). ScFv are monovalent mini-antibodies, that maintain antigen speciﬁcity and can be engineered
for intracellular expression or secretion.
So far, two groups have investigated the use of scFv in prion-infected cell culture system. One group
showed the paracrine inhibition of prion replication by RD-4 cells expressing and secreting scFv(6H4)
on co-cultured ScN2a (chronically prion infected neuroblastoma cells) [201]. Another interesting study
showed the retention of PrPC in the Endoplasmic Reticulum of HEK 293 and PC12 cells after the
expression of a scFv from antibody 8H4 and 8F9, containing the ER retention sequence KDEL [29].
Starting from these results a subsequent set of in vivo analysis were carried on showing that mice
intracerebrally injected with KDEL-8H4-NGF-diﬀerentiated PC12 cells infected with scrapie did not
develop scrapie clinical signs or show any brain damage [30].
Therefore, these data would support the use of scFv as therapeutic approach. Additional support
to the potential therapeutic value of intracerebral antibody production has recently been given by
two studies showing that brain delivery of either prion-speciﬁc scFv by adeno-associated virus (AAV)
transfer [202] or of a soluble prion antagonist (PrP-Fc2) by lentivirus transfer [203] delay the onset of
the disease in infected mice, although protection in these studies was not complete. Because infectious
prion replication occurs peripherally within the lymphoreticular system organs, the incomplete pro-
tection given by gene transferring of anti-prion molecules in the brain may be consequent to the fact
that the peripheral pool of PrPSc continues to replicate and then migrate to the CNS by neuroinvasion
[202].
In order to develop a system that could have therapeutic and not only prophylactic utility, in this
study we combined active and passive immunotherapeutic approaches. First, we have produced a
monovalent version of the anti-prion D18Fab, D18scFv, and we have tested it in prion-infected cells.
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The big improvement of our strategy compared to the previous gene transferring is that our molecule
might have eﬀects both peripherically and into the brain. We show here that this recombinant anti-
prion scFv is able to reduce PrPSc accumulation in diﬀerent infected cell models of prion diseases.
Since it was argued that D18Fab operates mechanistically by directly blocking or modifying in-
teraction of PrPC with PrPSc, we have used bioinformatics approaches to construct a structural
model of D18scFv-PrPC complex and deﬁne important interactions, which prevent prion propagation.
Based on the model of D18scFv-PrPC complex we propose the antigenic determinant of PrPC and the
mechanism through which D18scFv prevents interactions of PrPC with PrPSc or ﬁbrillation of PrPSc.
Furthermore, in order to provide a localized supply of D18scFv (that could obviate the needs of
repetitive injection in therapy), we have evaluated the in vitro eﬃciency of two virus-mediated gene
transfer systems. We produced two viral vectors, one based on recombinant AAV serotype 2 (AAV2)
and the other on HIV-1, carrying the D18scFv gene and showed that the latter one is more eﬃcient than
the AAV in reducing prion replication, at least in cultured infected cells in vitro. These results provide
additional support to the use of small antibody fragments for active and passive immunotherapy in
prion diseases and encourage the in vivo evaluation of an anti-prion scFv-based treatment for the
therapy of prion disorders.
6.1.1 Antibody fragments
Antibodies are immune system-related proteins called immunoglobulins. They are "Y" shaped molecules
composed of two identical long polypeptides (Heavy or H chains) and two identical short polypeptides
(Light or L chains) (Figure 6.2). The light chains have variable (VL) and constant (CL) domains,
while the heavy chains have a variable (VH) domain and three constant domains (CH1-3) (Figure
6.2).
Figure 6.2: Immunoglobulin molecules are composed of heavy chains (orange) and light chains (yellow)
joined by disulphide bonds so that each heavy chain is linked to a light chain and the two heavy chains
are linked together. The immunoglobulin molecule can be dissected by partial digestion with proteases
into three pieces, two Fab fragments and one Fc fragment. The Fab fragment contains the V regions
and binds antigen. The Fc fragment is crystallizable and contains C regions.
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All immunoglobulin domains are made up of two antiparallel β-sheet structures. The sheets are
linked by a disulphide bridge and packed to a β barrel or a β sandwich. The distinctive folded
structure of the antibody domains is known as the immunoglobulin fold. The variable domains, one
from the heavy and another from the light chain, form the two antigen binding sites, one at the
tip of each arm of the "Y" (Figure 6.2). The variable domains consist of hypervariable (HV) and
framework (FR) regions. The HV regions are represented as loops most closely involved in binding
to the antigen; called also complementarity determining regions (CDRs). Within light and heavy
chains exist three CDRs, CDRL1-3 and CDRH1-3, respectively, that diﬀer in length and sequence
among diﬀerent antibodies and are mainly responsible for the speciﬁcity (recognition) and aﬃnity
(binding) to their antigens. Four framework regions composed from β-sheets serve as a scaﬀold to
hold CDRs in position to contact an antigen. The constant domains determine the mechanisms for
antigen destruction.
Treating antibodies with a proteases release diﬀerent fragments termed (Figure 6.2):
1. Fab (Fragment antigen binding) - they correspond to the two identical arms of the antibody
molecule, which contain the complete light chains paired with the VH and CH1 domains of the heavy
chains. Fab fragments contain antigen-binding activity.
2. Fc (Fragment crystallizable) - was originally observed to crystallize readily, and for this reason
named the Fc. It corresponds to the paired CH2 and CH3 domains and is the part of the antibody
molecule that interacts with eﬀector molecules and cells. It contains no antigen-binding activity.
3. Fv fragment (fragment variable) - a truncated Fab comprising only the VH domain linked by
a stretch of synthetic peptide to a VL domain (see Figure 6.4A). This is called single-chain variable
fragment (scFv). scFv molecules may become valuable therapeutic agents because of their small size,
which allows them to penetrate tissues readily.
6.2 Computational details
The sequence of the D18scFv [27] was compared to the sequences of known 3D structures collected
in Protein Data Bank [1, 2] in order to ﬁnd templates for homology modeling. Three templates
were identiﬁed: the anti-(carcinoembryonic antigen) single chain Fv antibody MFE-23 (PDB code:
1QOK) [204], the anti-DNA binding antibody (PDB code: 2GKI) [205] and the anti-prion protein P
scFv fragment (PDB code: 2HH0) [206]. The anti-prion protein P scFv fragment was further used
as the template for modeling a 3D structure of D18scFv. 3D models were built using MODELLER
6v2 [48]. Amino acids of a signal sequence and poly-glycine parts of the sequences were neglected in
the modeling. The structure of the D18scFv model was then used to dock the prion protein (PrP;
PDB code: 1HJM) [180] by means of the HADDOCK2.0 program [207, 208]. Residues determined
to be important for protein-protein recognition between PrP and D18scFv fragment were reported in
the literature [27]. For the purpose of docking they were ﬁltered according to the solvent accessibility
with the NACCESS program [209]. The following residues were used as interactive residues in docking
process: (i) PrP - Ala133, Ser135, His140, Gly142, Ser143, Asp144, Tyr145, Arg148, Arg151, Glu152,
His155 (ii) D18scFv fragment - Tyr100, Tyr101, Gly102, Ser207, Asn208; Thr28, Asn54, Thr55,
Val57, Gly59, Ser141, Ser142, Ser143, Asn145, Thr146, Ser166. All His residues were deprotonated.
The remaining docking parameters were kept as default. Cluster analysis was then performed with
programs available in HADDOCK2.0.
All details about experimental can be found in ref. [210].
68 CHAPTER 6. D18 SCFV FRAGMENT IN PRION DISEASES THERAPY
Figure 6.3: Schema of the D18scFv in pET-22b(+). A: Sequence of the D18scFv. The diﬀerent
regions of the sequence are indicated with diﬀerent colors: the pelB leader is light gray, the VH and
VL sequences are red, the 20-AA linker is grey and the 6- histidine tag is yellow. B: Cloning of the
D18scFv in pET-22b(+). The D18scFv was obtained by PCR ligation of the variable regions of the
light [42] and heavy (VH) chains of FabD18, by inserting a 20-AA linker. The sequence corresponding
to the scFv (A) was inserted between BamHI and NotI restriction enzyme sites present in the multiple
cloning site of pET-22b(+) expression vector by keeping the pelB leader and the 6-histidine tag already
present in the vector.
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6.3 Results and discussion
It has been recently shown that anti-prion scFvs could be delivered to the central nervous system of
mice by adeno-associated virus (AAV) and are able to delay the onset of the disease when used in
prophylaxis but not when used after prion-exposure [202]. Contribution to the incomplete protection
could derive from down-regulation of the scFv expression by PrPSc neuroinvasion. In addition, because
infectious prions replicate peripherally within the lymphoreticular system organs, the incomplete
protection may be consequent to the fact that the peripheral pool of PrPSc continues to replicate and
migrate to the central nervous system by neuroinvasion. These observations make ineﬃcient anti-prion
treatments based exclusively on active immunotherapy. Since it has been shown that small proteins
can be rapidly delivered and spread in the brain after i.c. injection or after nasal administration
[211, 212], we have evaluated, in cell culture, an alternative approach to treat TSEs based on passive
immunotherapy. To this aim, we have produced a smaller version of the D18Fab, the D18scFv in
which the variable regions of the light and heavy chains of Fab were fused together. The sequence
corresponding to the scFv (Figure 6.3A) was cloned in a bacterial expression system (Figure 6.3B). In
order to directly test for interaction and anti-prion activity, D18scFv was evaluated for its binding to
PrP. We tested the ability of D18scFv to bind recombinant PrP and we found that D18scFv speciﬁcally
interact with PrP and competes with the Fab for its binding.
6.3.1 Molecular modeling of D18scFv-PrPC complex
Due to the interest on how D18scFv interacts with the PrPC , and consequently prevents formation
of PrPSc, we have used bioinformatics approaches to construct a structural model of D18scFv-PrPC
complex. Firstly, the 3D structure of D18scFv was modeled based on anti-prion protein P scFv
fragment (PDB code: 2HH0) [206]. The anti-prion protein P scFv fragment was crystallized in a
complex with a small peptide. Due to the presence of a small peptide, the scFv fragment represents
an open conformation, where complementarity determining regions 3 (CDR3) are further apart
than in non-complexed antibody structures. Therefore, this structure was taken as a template for
constructing the D18scFv model, since it allows an easy approach of the PrPC to the cavity of the
antibody in the docking procedure.
Like other single chain variable fragments also D18scFv is composed by heavy (VH) and light
(VL) hypervariable domains. CDRs of the heavy chain (H29-H33, H53-H57, H98-H105) and light
chain (L141-L146, L164-L166, L205-L210) form the paratope that interacts with the PrP residues
Ser132-Arg156 [27] (Figure 6.4A).
A D18scFv-PrPC complex was built by docking of PrPC (PDB code: 1HJM) to the model of
D18scFv (Figure 6.4A). According to the docking results ArgPrP 151 represent the antigenic determi-
nant, a key residue for interactions with the D18scFv (Figure 6.4B). An antigenic determinant is a site
on the antigen that the immune system responds to by making antibody and is frequently represented
by one residue on the antigen. ArgPrP 151 anchors the PrP to the cavity of the antibody forming
H-bonds with TyrV H32, AsnV H33, AspV H35 and TyrV L210, along with van der Waals interactions
with TrpV L205 (Figure 6.4B). In addition the Cß atom of ArgPrP 151 forms hydrophobic interactions
with the CE1 and CZ atoms of TyrV H32.
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Figure 6.4: Model of interactions between D18scFv and PrP. A: Complex of the D18scFv (silver) and
PrP (blue). Epitope residues of PrP (yellow) interact with the six CDR loops (red - CDR3, green -
CDR1,2) of the antibody fragment. B: Arg151 anchors the PrP to the antibody's cavity through the
H-bond and van der Waals interactions with Tyr32, Asn33, Asp35, Trp205 and Tyr210.
ArgPrP 151 seems important for recognition. But how D18scFv stabilizes the PrPC? A theoretical
study was done [213], where it was shown that PrPCβA-αA loop (residues 135 to 140 in the PrP
epitope) is directly involved in protoﬁbril formation (Figure 6.5A). Under certain conditions (e.g. low
pH) α helical formation of PrPC starts to convert to β strand rich PrPSc structure. A loop connecting
β A strand and α A helix of PrPC changes from random coil to β strand. The newly formed β strand
interacts with βA strand from other PrPSc molecule leading to the ﬁbrillation. When PrPC is bound
to the D18scFv, the βA-αA loop is stabilized by H-bond interactions (Figure 6.5B) and cannot convert
to β strand. Due to this stabilization the formation of ﬁbrils is prevented. The interactions stabilizing
βA-αA loop are formed by ArgPrP 136 and HisPrP 140 that are part of the long loop connecting βA
strand and α helix of PrP. The hydrogen atom from NH2 group of ArgPrP 136 interacts with the side
chain oxygen atom of ThrV H55 and the nitrogen atom Nε2 of HisPrP 140 accepts the H-bond from
the amidic oxygen of AsnV L208 or from the carbonyl group of SerV L207 (Figure 6.5B).
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Figure 6.5: A: It was argued that loop connecting βA strand and αA helix can convert to β strand,
interacts with βA strand of another PrPSc molecule and therefore enable prion aggregation. B:
Conversion of βA-αA loop is prevented when PrPC is bound to D18scFv due to the H-bond interactions
between the ArgPrP 136 and Thr55 among with the interactions of HisPrP 140 with the Asn208 or
Ser207.
A series of other H-bonds and hydrophobic interactions contribute further to the scFv-PrP complex
stability.
Additional H-bond interactions with the antibody are mostly formed by residues present in the
α helix of the PrP (Figure 6.6): AspPrP 144-LysV L167, TyrPrP 145-TyrV H100, AspPrP 147-TrpV L205
& TyrV L146, ArgPrP 148-TyrV H32, GluPrP 152-TyrV H52 and HisPrP 155-TyrV H52. In the cavity of
the antibody there are only few hydrophobic residues, namely TrpV H47, ValV H57 and TrpV L205.
Among them just ValV H57 forms hydrophobic interactions with the Cβ atom of SerPrP 135. In addi-
tion TyrV H50 and TyrV H52 form hydrophobic interactions with IlePrP 138 and MetPrP 154, respec-
tively. All other hydrophobic interactions involve the methyl/methylene groups of polar or charged
residues.
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Figure 6.6: Hydrophobic and H-bond interactions of the PrP epitope (Ser8 - Arg32; B) with D18 scFv
(A), as depicted by LIGPLOT [13]. Please note that the numbering of PrP residues shown above
diﬀers from the original one used in the text: Ser8 corresponds to Ser132 and Arg32 to Arg156 in the
original numbering (conversion: ligplot res+125=PrP res).
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6.3.2 In vitro studies of scFv
The next step in experiments was to test D18scFv for its eﬀect on scrapie replication in scrapie infected
cell lines (Figure 6.7).
Figure 6.7: Eﬀect of D18scFv in curing scrapie infected GT1 cells. ScGT1 cells were incubated for
1 week with diﬀerent concentrations (0.1; 0.5; 1 and 5 µg/ml) of scFv refolded at diﬀerent pH (pH
6.5; 7.5 and 8.5). As controls, R2 (10µg/ml) and D18Fab (1 and 5 µg/ml) were used. PrPSc present
in cell lysates was digested with Proteinase K (PK +) as described in Experimental and detected by
western blot by using SAF61 antibody. Note that scFv reduces PrPSc level of 20%±4, 50%±7, 80%±3
and 95%±1 by using respectively 0.1, 0.5, 1 and 5 µg/ml D18scFv. Blots of PK-resistant assays were
quantiﬁed by ImageJ (n=3) and Student T-test was used to calculate signiﬁcance of data (p<0.05).
No diﬀerence was found among the scFvs refolded at the diﬀerent pH.
scFv was found to reduce PrPSc levels similarly to what was found for the Fab in ScN2a cells
[28]. Interestingly, the same concentration of Fab and scFv is required to achieve the same extent of
reduction in PrPSc level. However, since the scFv is approximately half molecular weight compared
with the Fab, D18scFv is 2-fold less eﬀective than Fab with respect to the reduction of the PrPSc
level in ScGT1 cells. After 1 week treatment, PrPSc was reduced to undetectable levels but was not
completely eliminated from the cells because it reappeared after 1 additional week of growth in the
absence of the scFv. However, after 2 or 3 weeks of scFv treatment PrPSc remained undetectable
for up to 3 weeks of culture without adding any scFv, as it has been shown for the original Fab [28].
These data indicate that the small monovalent antibody fragment, scFv, might be a very useful tool in
therapy because it is able to interfere with prion metabolism (either reducing conversion or promoting
degradation) in infected cells. The big improvement of our strategy compared to the previous gene
transferring-based approaches [202] is that our molecule might have eﬀects both peripherically and
into the brain, both of them sites of prion replication. In vivo the putative anti-prion eﬀects of
the D18scFv expressed as recombinant protein might be enhanced by combining passive and active
immunotherapeutic approaches.
74 CHAPTER 6. D18 SCFV FRAGMENT IN PRION DISEASES THERAPY
Recently, diﬀerent gene transfer approaches in anti-prion prophylaxis of infected animals have
been successfully used by using either lentivirus carrying a soluble prion antagonist [202] or AAV
transducing either anti-LPR/LR [32] or anti-prion protein speciﬁc scFvs [202]. Therefore, in order to
have a continuous supply of our recombinant scFv to be eventually used in immunotherapy in animals
and to test the eﬀectiveness of these two viral systems, we cloned the gene encoding for D18scFv
(Figure 6.3A) either in a defective lentiviral vector (Figure 6.8A, left panel) or in an AAV vector
(Figure 6.8A, right panel). Lentivirus carrying the D18scFv was titered and tested for its eﬀectiveness
in reducing PrPSc content in infected ScGT1 and ScN2a cell cultures. One week posttransduction
D18scFv was expressed (Figure 6.8B) and the levels of PrPSc were reduced of 80%±7 and 90%±3
respectively in ScGT1 and ScN2a cells by using the highest viral titer tested (10x106 TU) (Figure
6.8C). Interestingly, the eﬀect on PrPSc content after lentivirus transduction was more pronounced in
ScN2a cells, where even a lower titer of 10x104 TU was eﬀective (Figure 6.8C). Alternatively, we also
produced a recombinant (rec) AAV2 expressing D18scFv. Titers of 10x1010 up to 10x1012 TU were
used to transduce both ScGT1 and ScN2a cells and transgene expression (Figure 6.8B). One week
post-transduction only the highest titer tested (10x1012 TU) was able to reduce PrPSc level of 20%±5
in ScN2a cells (Figure 6.8C).
We have shown that, at least in cell culture models, lentivirus transduces D18scFv in a functional
form able to prevent or interfere with PrPSc conversion and seem to represent a better delivery system
compared to AAV. However, AAV-scFv remains a valuable potential tool for the in vivo treatment of
prion disease. How these viruses act in reducing PrPSc levels has to be still elucidated. One possibility
could be that anti-PrP scFvs block conversion reaction directly. Alternatively, PrPSc reduction could
be an indirect eﬀect of down-regulation of PrPC expression. Nevertheless, the eventual regulation of
PrPC expression is speciﬁcally due to the scFv, because viruses expressing other constructs (GFP-PrP)
do not reduce PrPSc content in scGT1 cells.
6.4 Conclusions
In conclusion, we validated here the use of D18scFv as potential anti-prion immunotherapeutic both
as puriﬁed protein and after viral transduction in cultured neuronal cells. The availability of our
lentiviral and AAV2 vectors expressing the same therapeutic molecule will now allow us to directly
compare the eﬃcacy of the two viral vectors in sick animals in vivo. With bioinformatics approach we
modeled D18scFv-PrPC complex and deﬁned ArgPrP 151 as the antigenic determinant important for
the recognition between the two proteins. We proposed that H-bond interactions of ArgPrP 136 and
HisPrP 140 with the D18scFv stabilize PrPC and therefore prevent ﬁbrillation process. All these data
give new suggestions for mutational studies that will elucidate the exact mechanism of action for the
D18scFv.
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Figure 6.8: Production and cellular test of lentivirus and AAV2 containing the D18scFv. A: Cloning
of the D18scFv in pTTLsin.PPT.hPGK.GFPpre and in pAAVMCS. For lentiviral vector production
(left panel), the gene encoding for D18scFv (Figure 6.3A) was cloned in defective lentiviral vector
(pTTLsin.PPT.hPGK.GFPpre) between AgeI and SalI restriction enzyme sites. The signal peptide
of the PrP sequence was cloned upstream between BclI and AgeI. For AAV vector production (right
panel), the gene encoding for D18scFv was cloned in pAAV-MCS between HindIII and BglII restriction
enzyme sites. For secretion, the signal peptide of the immunoglobulin (Ig) sequence was added between
HindIII and ApaLI. B: Expression of D18scFv after transduction of ScGT1 and ScN2a cells. 10x104
TU of lentivirus and 10x1010 TU of rAAV2 were used to transduce both ScGT1 and ScN2a cells.
One week post-infection, D18scFv expression was tested by western blot by using an anti- 6his tag
antibody. C: Eﬀect of the lentivirus and rAAV2 carrying the D18scFv in curing scrapie infected
neuronal cell lines. Titers of 10x104-10x106 TU of the lentivirus (left panels) and 10x1010-10x1012
TU of rAAV2 (right panels) carrying the D18scFv were used to infect both ScGT1 and ScN2a cells.
One week post-infection, PrPSc present in cell lysates was digested with proteinase K (PK +) as
described in Experimental and detected by western blot by using SAF61 antibody. Blots of PK-
resistant assays were quantiﬁed by ImageJ (n=3) and Student T-test was used to calculate signiﬁcance
of data (p<0.05). By using increasing titer of lentivirus, levels of PrPSc were reduced of 2%±7, 75%±3
and 80%±7 in ScGT1 and 76%±2, 80%±7 and 90%±3 in ScN2a cells. By using increasing titer of
AAV2, levels of PrPSc were reduced of 2%±3, 5%±3 and 5%±4 in ScGT1 and 4%±2, 4%±7 and
20%±5 in ScN2a cells. Note that levels of PrPSc were signiﬁcantly reduced in both cell systems by
using the highest lentiviral titer tested (10x106 TU).
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Chapter 7
A Computational Protocol for
Docking Ligands to the PrP
Abstract
Molecular docking of ligands targeting proteins undergoing ﬁbrillation in neurodegenerative diseases is
diﬃcult because of the lack of deep binding sites in these proteins. Here we combine standard docking
methods with MD simulations and bias-exchange metadynamics based-free energy calculations in
explicit solvent to address this issue in the context of the prion protein. We focus on the GN8 ligand
(2-pyrrolidin-1-yl-N-[4-[4-(2- pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide) , which has been
shown to bind to the structured part of the protein, increasing its stability. Our calculations enable to
identify alternative GN8 binding poses that satisfy all of the contacts emerging from NMR, in contrast
to a previous model. Most importantly, our results provided an estimation of the experimental free
energy of binding which is in very good agreement with the experimental one. We conclude that our
approach is a useful tool to predict poses and aﬃnity of ligands binding to proteins with ﬁbrillation
properties.
This work was carried out in collaboration with S. Bongarzone, G. Rossetti, X. Biarnes (Statistical
and Biological Physics Sector, SISSA/ISAS).
7.1 Introduction
Recent developments in molecular docking protocols (MDPs) allow to predict accurately ligand poses
in their target binding sites [214, 215]. In many cases, the reason of their success lies in the coupling of
traditional scoring function-based approaches with molecular simulations [216, 217] which introduces
conformational ﬂexibility of the target. This is very useful because proteins are in constant motion
between diﬀerent conformational states [218, 219] that may be further altered when a ligand is bound
[219]. Diﬀerent methods were proposed to address these issues, among them: soft harmonic modes
[220], molecular dynamics simulations [221, 222, 223, 216] and relaxed complex method [224].
In spite of these successes, there are still many important cases for which MDPs are challenged.
These include, the prediction of the poses of transition-metal and/or alkylating drugs, of ligands
causing large structural changes, and of ligands not binding to speciﬁc pockets. The latter case
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is crucial in most targets undergoing ﬁbrillation in neurodegenerative diseases. Here we use the
metadynamics along with MDP (Figure 7.1) to predict ligand binding poses onto protein surfaces
for which a speciﬁc binding pocket is not deﬁned. Metadynamics [33] has recently been shown to
uncover molecular and energetics aspects of the drug binding mechanisms when the binding sites are
well characterized by X-ray crystallography or NMR experiments [225, 226, 227, 228].
Figure 7.1: Our hybrid computational protocol combines docking, MD simulations and metadynamics
technique (Advanced Molecular Docking).
We focus on a small organic molecule able to bind to the cellular form of human prion protein
(hPrPC), which can interfere with its conversion to the pathogenic form (hPrPSc, scrapie prion protein)
[26]. This in turn is involved in the epidemics of bovine spongiform encephalopathy (BSE) and,
possibly, in the new variant Creutzfeldt-Jakob disease (nvCJD) [24, 191, 229, 230, 231], for which
there is neither early diagnosis nor a cure [232, 191, 229, 230].
Recently, chemical shift perturbations and binding aﬃnity of a PrP-binding ligand, GN8 (2-
pyrrolidin-1-yl-N-[4-[4-(2- pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide, Figure 7.2) [35], have
been measured for the mouse prion protein (mPrPC), which is highly similar to the hPrPC (Seq. Sim-
ilarity=98%).
The reported chemical shifts perturbations of mPrPC induced by GN8 binding aﬀect most signif-
icantly amino acid residues on one side of the protein surface (Asn159@H1-S2 loop, Val189, Thr192,
Lys194@Helix H2 and Glu196@ H2-H3 loop). In addition, Val189 and Thr192, located on the other
side of the PrP surface, are also perturbed [35] (Figure 7.4A and Table 7.1). This suggests that mul-
tiple binding sites may be present. In fact, an ad hoc model of the mPrPC-GN8 adduct, constructed
by docking and energy minimization exhibited a single binding mode of GN8 connecting Asn159 and
Glu196 [35]: such single binding mode could not explain the contacts with Val189 and Thr192.
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Figure 7.2: GN8 (2-pyrrolidin-1-yl-N-[4-[4-(2- pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide)
molecule.
Here we have applied our computational protocol to identify ligand binding modes of the GN8
molecule on the surface of the hPrPC . Our calculations provide multiple binding modes of the ligands,
consistent with all of the NMR contacts. Most importantly, it provides energetics in agreement with
experimental data. The computational approach emerges therefore as a useful approach to investigate
ligands sticking on protein surfaces.
σ>0.9 ppm 0.5ppm<σ<0.9 ppm
Asn159 Arg156
Val189 Glu196
Thr192 Thr199
Lys194
Table 7.1: NMR chemical shift changes (σ) upon GN8 binding to the mPrPC .
7.2 Computational details
Identiﬁcation of binding sites. The residues interacting with GN8 are located in hPrPC C-term,
for which the NMR structure is available (residues 125-228, PDB ID: 1HJM) [233]. Protonation states
were assigned by the web server H++ [234, 235] assuming pH 7.4.
Putative binding sites were identiﬁed by (i) molecular simulations (using the GROMACS pack-
age [155] and (ii) docking procedure (using the GOLD [56, 57, 58, 236] and the Autodock programs
[59]).
(i) Molecular simulations. The protein was inserted into a cubic box of water molecules, ensur-
ing that the solvent shell would extend for at least 8 Å around the system. Three sodium counterions
were added. The AMBER99 force ﬁeld [149, 237] was used for the protein. Sodium ions were modeled
with the AMBER-adapted Aqvist potential [161]. The water molecules were described by the TIP3P
model [66]. The system was minimized imposing harmonic position constraints of 1000 kJ/(mol*nm2)
on solute atoms, allowing the equilibration of the solvent without distorting the solute structure. After
an energy minimization of the solvent and the solute without harmonic constraints, the temperature
was gradually increased from 0 to 298 K. This was performed by increasing the temperature from 0
to 298 K in 12 steps in which the temperature was increased by 25 K in 100 ps of MD. Constant
temperature-pressure (T=298 K, P =1 bar) 20-ns MD dynamics was then performed through the
Nose-Hoover [81, 80] and Andersen-Parrinello-Rahman [238] coupling schemes. Periodic boundary
conditions were applied. Long-range electrostatic interactions were treated with the particle mesh
Ewald (PME) [76, 78] method, using a grid with a spacing of 0.12 nm combined with a fourth-order
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Figure 7.3: Titration curve of GN8. At the pH of the Kd measurements , it is present in neutral (10)
and monoprotonated (1+) states. At the pH of the NMR measurements , it exists in diprotonated
(12+) form.
B-spline interpolation to compute the potential and forces in between grid points. The cutoﬀ radius
for the Lenard-Jones interactions as well as for the real part of PME calculations was set to 0.9 nm.
The pair list was updated every 2 steps, and the LINCS algorithm [151] was used to constrain all
bond lengths involving hydrogen atoms allowing us to use a time step of 2 fs.
The MD trajectory of prion protein alone was clustered with the program gromos [239] and as
result 20 diﬀerent conformations were obtained, which were used along with the NMR structure for
the docking of GN8 compound.
(ii) Docking. Titration curves, as calculated by the ChemAxon software [240], suggested that
GN8 molecule is present in two protonation states (neutral, 10 and monoprotonated, 1+) in aqueous
solution at pH=7.4, while at pH=4.5 exists also in diprotonated form (12+) (Figure 7.2 and 7.3).
This method has been used because it appears to be rather reliable: in a calculation of pKa of
1000 molecules, less than 0.5 % calculations turned out to diﬀer by more than 0.5 pH unit from the
experimental value [240]. All three protomers underwent geometry optimization at the B3LYP/6-
31G** level of theory by means of the Gaussian03 software (g03) [241]. The optimized structures, 10,
1+ and 12+, were docked to the NMR structure of hPrPC and to its 20 diﬀerent conformations.
The GOLD 3.1 [57] and Autodock 3.0.5 [59] programs were used. In GOLD, the docking area
was deﬁned as a sphere of 35 Å radius around the His187, so that the whole protein was screened.
The ChemScore (CS) [242, 243, 62] and GoldScore (GS) [244, 245] scoring functions were used for
ranking. For each protomer and scoring functions, 100 docking runs were performed. In Autodock,
a Lamarckian genetic search algorithm was used to identify low energy binding sites and orientations
of GN8 protomers. Binding modes were ranked by a scoring function implemented in the Autodock.
A point grid with a spacing 0.475 Å was used. Point grid was centered to the center of mass of the
protein, its dimensions were 126 Å x 126 Å x 126 Å. Gasteiger atom charges were assigned to the
proteins using AutoDockTools. Water molecules were excluded from the protein before docking. 100
randomly seeded runs were performed. The binding poses were identiﬁed by AClAP 1.0 clustering
procedure [246, 247].
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Hydratation and thermal stability of GN8- hPrPC adducts. 10-ns MD simulations of the
adducts (hPrPC-10, hPrPC-1+ and hPrPC-12+) allowed for a proper hydration of the system and for
identiﬁcation of collective motions that may be essential for PrP-ligand interactions. The protomers
were bound to the binding site I. The simulation protocol was the same as for the free protein. For the
three ligands, the gaﬀ force ﬁeld [248] was used. The atomic restrained electrostatic potential (RESP)
charges [249, 250] were calculated by using the resp module of AMBER after geometry optimization
and wave function relaxation.
Binding free energy calculations. The binding free energies of 10, 1+ and 12+ were calculated
using metadynamics [33] in its bias-exchange variant [34], as a function of collective variables (CVs)
which should be relevant for describing the dissociation process. Those chosen here included: (i) the
distance between the center of mass of the ligand and the center of mass of the protein binding region;
(ii) the number of polar contacts between the ligand and one portion of the protein binding region;
(iii) the number of polar contacts between the ligand and the other portion of the protein binding
region; (iv) the number of water bridge contacts between the ligand and the protein binding region;
(v) the RMSD diﬀerence of the system with respect to an equilibrated MD structure taken from the
previous Section; (vi) the RMSD ﬂuctuation of the residues deﬁning the protein binding site. This set
of CVs does not require the previous knowledge of the protein-ligand adduct structure, but is limited
to the exploration of a region around the previously deﬁned binding site I. The choice of such CVs was
dictated by previous ligand-target interaction metadynamics studies [225, 227, 226, 228] as well as by
observations based on the former MD simulations. For further details on this theoretical approach see
Appendix 7.4.
Six independent metadynamics simulations were run in parallel. Each replica was biased by diﬀer-
ent one-dimensional time-dependent potentials, which were built as a function of each of the collective
variables deﬁned above. Exchanges among replicas were attempted every 10 ps by a Metropolis accep-
tance criterion [34]. Similar set-up has shown to improve the sampling of the conﬁgurational space and
the convergence of the results [34, 251]. At the end of the diﬀerent replica simulations, the explored
phase space, in terms of the six collective variables used here, was clustered using the gromos method
[239]. The clustering radius for each collective variable was set to 0.1 nm, 0.2, 0.4, 2.5, 0.05 nm,
0.02 nm, respectively. The free energy corresponding to each cluster was then reconstructed from the
populations of clusters observed during the simulations. The free energy value was corrected by the
corresponding bias potentials acting on that cluster as in a usual weighted histogram analysis [252].
Two reference states of the ligand-protein system, bound and unbound, needed to be deﬁned to
provide the corresponding binding free energy value. The bound state was here considered as the
lowest free energy cluster. The unbound state was considered to be a cluster showing no contacts with
the binding site I (lowest values of CVs ii and iii) and at the same time with a higher RMSD with
respect to the initial docked structure (highest value of CV v). Given the size of the simulation box
the ligand is not fully detached from the protein in its unbound state. Therefore, the residual binding
energy in the unbound state was roughly estimated in implicit solvent using an adaptive Poisson
Boltzmann solver [253]. It was estimated as the diﬀerence in solvation energy of the complex minus
the solvation energy of each component plus the intermolecular Coulombic interaction. The standard
free energy of binding was obtained by applying the following relationship: ∆G0 = ∆G+RT log([L]),
where ∆G is the total binding free energy as a result of our simulation, R is the molar constant, and
[L] is the concentration of the ligand in our simulation box (i.e. 5.5 mM). The standard free energy
is related to the dissociation equilibrium constant (Kd) by ∆G0 = −RT log(Kd).
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7.3 Results
In this study, we set up a computational protocol to dock small molecules targeting cavity-less proteins
such as hPrPC . As prototype we used known active compound GN8 (2-pyrrolidin-1-yl-N-[4-[4-(2-
pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide), for which there are NMR chemical shifts and
energetic information available [35].
Putative GN8 binding sites of hPrPC . GN8 is a symmetric molecule, composed by two
phenyl and pyrrolidin rings connected by acetamides. pKa calculations allowed us to suggest that at
pH=7.4, at which the Kd has been measured, the GN8 is present in neutral (10) and monoprotonated
(1+) form; while at pH=4.5, at which the NMR experiments have been performed, exists in the
diprotonated (12+) form (Figure 7.2 and 7.3). Therefore, the three protomers were docked onto the
hPrPC NMR structure and its 20 conformers. Notice that the sequence identity between hPrPC used
in calculations and mPrPC used in experiments is very high (98%). In particular, all of the residues
involved in GN8 binding are fully conserved. In addition, the RMSD of the Cα between the 20
hPrPC conformational structures is not very dissimilar from that between mPrPC and hPrPC NMR
structures (2.4 ±0.1 Å nm and 2.7 Å, respectively). Therefore, we do not expect large changes of the
results upon performing simulations either in the mouse or human protein.
Figure 7.4: A: The NMR-deﬁned binding site. Residues that exhibit signiﬁcant chemical shift as
reported in ref. [35] are shown in licorice. B: The three diﬀerent binding sites I (shown in blue), II
(depicted in red) and III (highlighted in yellow) obtained after docking of GN8 to diverse conforma-
tional structures of hPrPC . Orange balls represent amino acids deﬁned by NMR chemical shift study
to interact with GN8 compound.
As a result of docking procedure, binding sites I, II and III were determined (Figure 7.4B). I
is deﬁned by H2 helix and the loop connecting β-sheet S2 and helix H1. II is deﬁned by H2 and
H3 helices. III, is represented by H3 helix, H2 helix N-term, and the loop between H1 helix and S1
β-sheet. I is the only site which involves residues changing chemical shifts upon GN8 binding and it
was the only one selected for further calculations.
Adducts with the three protomers bound to this location underwent therefore 10-ns MD calcu-
lations in aqueous solution. After ∼ 3 ns of MD simulations, 10 partially slided out of the binding
pocket I. In its ﬁnal conformation, the GN8 amidic oxygen (O2, Figure 7.2) formed H-bond interac-
tions with Lys194. The pyrrolidine ring formed hydrophobic interactions with methylene groups of
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Glu196 and Arg156. The two aromatic rings formed also hydrophobic interactions with the methylene
groups of Lys194. Water molecules can be involved in protein-ligand recognition by forming mediating
hydrogen bonds between the protein and the ligand. In this regard, water-mediated H-bond contacts
were identiﬁed between hPrPC and protomers during the MD simulations. The amidic nitrogen of
10 protomer formed water mediated H-bond with carbonyl oxygen of Arg156, with hydroxyl group of
Thr190 or imidazole nitrogen of His187.
Instead, 1+ and 12+ remained stable during the MD simulations relative to initial docked structure.
The amidic nitrogen atom of both protomers (N3; Figure 7.2) H-bonded to backbone oxygen of Glu196.
The carbonyl oxygen (O5, Figure 7.2) of 1+ H-bonded with the backbone amino group of Asn159. In
addition, phenyl rings of 1+ formed hydrophobic interactions with the methylene groups of Arg156 and
T-stacking interactions with the His187. During the MD the protonated nitrogen atom (N1, Figure
7.2) of 1+ formed direct or water mediated H-bond with the carboxylate side chains of Asp122. The
protonated N6 atom of 12+ formed water mediated H-bond with the side chain oxygen of Asn159.
Electrostatic interaction was present among carboxylate of Glu196 and N1 atom of 12+. Hydrophobic
interactions between the diphenylmetane fragment of 12+ and methylene groups of Lys194 and Arg156
stabilized further the binding of 12+.
The structural determinants emerging from our MDP protocol turned out to be consistent with all
of the ligand-protein contacts identiﬁed by NMR (Table 7.1) except for Val189, Thr192 and Thr199. A
docking approach, combined with energy minimization provided similar results (Figure 3 in ref. [35]).
Based on these results, we proceed using a more sophisticated method which attempts at identifying
ligand poses in agreement with experiments.
This is bias-exchange metadynamics (BE-META) simulations, which allows to reconstruct the
binding free energy proﬁle associated to the simulated process of dissociation. The free energy was
here calculated as a function of a large number of collective variables necessary for describing the
complex binding process (see methods).
hPrPC-10 complex. 10 global minimum is located in the wide cleft formed by helices H1, H2 and
H3, similarly to I and the minimum identiﬁed by Kuwata et al. for mPrPC . The contacts 10 formed
with the hPrPC are consistent with the reported chemical shift changes on Arg156, Thr199, Glu196
upon GN8 binding . The phenyl groups of 10 form a cation-pi interaction with Arg156 and a water-
mediated hydrogen bond is present between Thr199 and the pyrrolidine nitrogen (N1; Figure 7.2).
Other water mediated interactions observed for 10 in previous MD simulations are not observed here.
In contrast to MD, Thr190 forms a direct hydrogen bond with the carbonyl group of 10 compound
(O2; Figure 7.2). This is an indication that MD simulations were hindered in a pre-stationary state
in which the release of intermediate water molecules is necessary to reach the global minimum. This
now arises when combining MD simulations with metadynamics. The hPrPC-10 complex is further
stabilized by hydrophobic interactions between the pyrrolidine ring and Thr183 and Pro158.
The unbound state of hPrPC-10 system (10.U1 in Figure 7.6A) corresponds to a conformation in
which the ligand is not forming any contact with the protein. Lys194 showed a remarkable conforma-
tional change of the backbone upon ligand binding (Figure 7.5). This is consistent with the signiﬁcant
chemical shift change reported for this amino acid . Smaller conformational changes were observed for
other residues present in the H2-H3 loop. These rearrangements were not observed with previously
used MDP techniques, because they are induced during the ligand binding process simulated here.
This unbound state is 5.5 kcal·mol−1 ± 0.9 kcal·mol−1 higher in energy with respect to the global
minimum. The ligand is not completely detached from the protein (although already 5 layers of water
molecules between the two moieties are present). The remaining free energy for complete dissociation
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Figure 7.5: Ramachandran plot of residue Lys194 for the unbound state (empty squares), and bound
states (crosses) of the hPrPC-10 adduct.
was estimated to be -0.7 kcal·mol−1 by means of the Poisson-Boltzmann equation (see methods).
Thus, we estimate the dissociation free energy to be 4.7 kcal·mol−1 in our simulation conditions.
Considering also the concentration of the species in the simulation box, the standard free energy of
dissociation is 7.8 kcal·mol−1. This is in very good agreement with the experimental value of 7.5
kcal·mol−1 (corresponding to Kd=3.9 µM) reported by Kuwata et al. [35].
hPrPC-1+ complex. In the global minimum, 1+ lies along the loop that connects helices H2 and
H3 (1+.B1 in Figure 7.6A). It forms a remarked hydrophobic interaction with Thr199, consistently
with the chemical shift changes reported for this group . The amidic nitrogen atoms of 1+ (N3 and N4;
Figure 7.2) are H-bonded to Thr201 and Asn197 respectively. This induces a subtle conformational
change of the Glu196 and Asn197 backbone upon ligand binding which may be the reason for the
chemical shift displacement reported experimentally for Glu196. Additionally, the neutral pyrrolidine
ring of 1+ is kept by the hydrophobic cleft formed by Val203, Met206, Ile184, Thr188 and Phe198,
further stabilizing the complex. No water-mediated interactions were observed between 1+ and hPrPC .
The free energy diﬀerence between the bound state of 1+ (1+.B1 in Figure 7.6A) and the corre-
sponding unbound state is 5.3 kcal·mol−1. The remaining free energy for complete dissociation was
estimated to be 0.2 kcal·mol−1 (see methods). Thus, we estimate the dissociation free energy to be
5.5 kcal·mol−1± 0.9 kcal·mol−1. Correcting by the concentration of the species in the simulation box,
the standard free energy of dissociation turns out to be 8.6 kcal·mol−1, that is a similar value than
that predicted value for 10 and in good agreement with experiments.
hPrPC-12+ complex. The most stable conformation of 12+ binds yet in another position of
hPrPC , laying along helix H2 (12+.B1 in Figure 7.6A). Half part of 12+ is in strict contact with
hPrPC surface in the cleft formed by Thr192, Thr193 and Val189 by means of hydrophobic interac-
tions. Indeed, these positions were reported to interact directly with the ligand according to NMR
experiments . However, the second part of 12+ is quite distanced from binding surface due to the
presence of Lys185. Two water molecule layers in between the PrP/ligand interface are responsible
for the ﬂuctuation of the ligand in the binding pocket. A value of free energy here was not calculated,
as this protomer is present in the conditions of the NMR experiment , but not in the conditions in
which the aﬃnity has been measured.
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In summary our protocol enabled us to identify the alternative binding poses of the GN8 compound
to hPrPC and to provide an accurate estimation of the experimental dissociation constant. The
multiple binding sites pattern that we observed from our simulations (Figure 7.6B) allows for justifying
the NMR-contacts observed in distant positions of hPrPC which are located in opposite sites of the
protein surface (Arg156, Thr199, Glu196, Thr192, Val189) . This pattern could not be observed
applying only standard MD, and was not observed in the study reported by Kuwata et al. [35] where
a single binding mode was proposed.
Figure 7.6: A: Representative three dimensional structures of the hPrPC complexes with the 10,
1+ and 12+ protomers. Ligand structures are colored according to their relative free energy values
(B-bound state; U-unbound state). B: Comparison of the GN8 binding modes for each of the three
protonation states on hPrPC surface. Yellow: neutral state (10); Red: protonated state (1+); Blue:
diprotonated state (12+). The amino acids showing a change in NMR chemical shift upon ligand
binding [35] are highlighted in orange.
7.4 Conclusions
Predicting the binding mode of small ligands to the protein surface is a challenging task from the com-
putational point of view. We have presented here a hybrid protocol that overcomes these limitations.
Our protocol combines molecular docking with rare events simulation techniques (molecular dynam-
ics coupled to bias-exchange metadynamics). The integration of docking algorithms with molecular
dynamics based simulations has already shown to be convenient in computer assisted drug design
[221, 224]. We showed here that this can be extended with free energy calculations in order to get an
accurate prediction of the binding modes and the thermodynamic stability of the complexes. Similar
approaches have already been followed [225, 228, 227].
This protocol has been validated with the binding of a small compound (GN8) [35] to the cellular
86 CHAPTER 7. A COMPUTATIONAL PROTOCOL FOR DOCKING LIGANDS TO THE PRP
form of prion protein (hPrPC), the main agent involved in prion diseases. GN8 compound can adopt
diﬀerent protonation states at physiological and acid pH, at which experiments have been carried out.
We identiﬁed diﬀerent binding patterns for each of them. Neutral state binds in a speciﬁc region of
hPrPC surface along the shallow cleft formed by helices H1, H2 and H3, while the protonated state
bind in multiple sites of hPrPC surface. The characteristic binding of this molecule is in agreement
with the distant contacts with the prion protein reported experimentally by NMR studies [35]. The
calculated free energy agrees with the experimental value.
Given the lack of deep binding pockets along hPrPC protein structure, it is reasonable that a small
molecule will not bind speciﬁcally to a single site. NMR data shows that this is indeed the case [35].
Consistently, we have observed a multi-binding mode for the GN8 ligand, not emerging from standard
MDP protocols. Our simulations predict an unspeciﬁc binding of the diﬀerent protonation states of
GN8 compound on multiple sites of hPrPC surface. The diﬀerent binding modes allow justifying the
experimentally predicted contacts of GN8 compound with distant regions of the protein [35]. These
alternative binding modes could be predicted only when simulating the whole binding process of GN8
compound from solution to the protein surface for each protonation state independently. In conclusion,
molecular simulations approaches appear as a valuable tool to predict poses and energetic of ligands
binding to protein surfaces.
Concluding remarks
We have addressed issues related to the structural predictions and docking of systems relevant for
molecular pharmacology, especially for proteins of great importance in neurobiology.
Ca2+-gated potassium (hBKCa) and chloride (bestrophins) channels play a key role for the sig-
naling in neuronal, muscular and epithelial tissues [9, 10, 11, 12, 118, 119, 117]. Failure of their
physiological function leads to degenerative diseases [14, 15, 7]. Understanding the structural deter-
minants is crucial to address the problems related to the function. To gain structural information of
these channels, we have here applied molecular modeling techniques.
The structural determinants of two diﬀerent hBKCa Ca2+-binding domains were predicted. These
are the RCK1 domain (Regulator of Conductance of K+) and the Ca2+ bowl. A structural model
of the RCK1 domain was constructed based on two templates: the RCK domains of E. coli [97] and
MthK K+ [91] channels. Our model points to a key role of the salt bridge among K513 and D546.
This is consistent with experiments of site directed mutagenesis, which showed the importance of
the predicted salt bridge in stabilizing the domain. Next, the Ca2+ bowl including ﬁve Ca2+ ions
was constructed and its stability was studied by MD simulations. Two Ca2+ ions remained stably
bound. One binding site was formed by residues D959, D961, D963 and E967. Mutations to Ala
of Asp residues forming this binding site were shown experimentally to reduce Ca2+ binding and/or
sensitivity from 50% to 90% with respect to the wild type channel [21, 22], consistently with our
model. The second ion was bound to E946, D950, D957 and D962. All these residues except Asp950
when mutated to Ala reduced Ca2+ binding and/or sensitivity from 30% to 90% with respect to the
wild type BKCa [21, 22]. Again, these results are consistent with our predictions.
Bestrophin is suggested to be a Ca2+-gated Cl− channel [6]. It contains a Ca2+-binding motif
very similar to that of hBKCa Ca2+ bowl [20, 21]. Structural models of the Asp-rich domain and its
mutants were constructed including diﬀerent numbers of Ca2+ ions. By performing extensive molecular
simulations, two well formed Ca2+-binding sites were identiﬁed. Residues involved in Ca2+-binding,
D301, D304, E306 and D312, were proposed for experimental mutational studies. Electrophysiological
experiments indeed conﬁrmed that mutations D301A and D304A decreased the Ca2+-activated current
amplitude, as predicted by our modeling. On the other hand, mutations E306A and D312A did not
cause reduction in the current consistently with the simulations: in fact, neutral residues such as Asn,
Gln and Ser replace the aforesaid residues in the Ca2+ coordination shell. These results support the
importance of the Asp-rich domain in Ca2+-dependent activation of the bestrophins and shed light
on its structural features.
The second part of the thesis focuses on docking of mini-antibodies and ligands to a protein
involved in neurodegeneration, the prion protein. Many key proteins involved in neurodegenerative
diseases (such as α-synuclein in Parkinson disease, β-amyloid in Alzheimer disease or prion protein in
prion disease) exhibit the ability to aggregate, what consequently causes the damage of neurons [254].
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Therefore, due to these similar features, ﬁnding a treatement for one of these diseases may help to
address also the others.
We studied the interactions between the small antibody fragment D18scFv and the prion protein
in collaboration with experimental groups. Our experiments have shown that the small antibody
fragment D18scFv binds to the prion protein and prevents its conversion to the pathological form. To
get insight into the mechanism by which D18scFv prevents the conversion and propagation of prion
proteins, a structural model of D18scFv was constructed and the prion protein was docked onto it.
Based on our results, we suggested that Arg151 is the antigenic determinant of prion protein, i.e.
it is the key residue for the recognition between the two proteins. In addition, we proposed that
interactions of ArgPrP 136 and HisPrP 140 with D18scFv stabilize PrPC and therefore prevent the
ﬁbrillation process.
An alternative to immunotherapy is the design of small ligands binding to the prion protein. Small
compounds may stabilize the cellular prion protein conformation or modify the binding of molecular
chaperon, which enhances prion protein conformational conversion [26, 190, 191]. Unfortunately,
prion proteins lack the cavities (unlike enzymes and receptors) which allow for eﬃcient docking and
high throughput screening, ﬁrst steps in design of new ligands. Here we have addressed this issue
by proposing a new computational protocol to address the problem of ligands binding to a protein
surface. To this aim, standard docking methods were combined with MD simulations and free energy
calculations. The protocol was tested on the known anti-prion compound (GN8), and compared with
experimental data [35]. It turns out that the combination of the three methods of the protocol is
necessary to satisfy contacts experimentally detected by NMR spectroscopy [35]. In addition, this
approach allows to predict the binding free energy, which for GN8 [35] is in very good agreement with
the experimental value.
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Appendix
Additional computational details for the PrP docking protocol
In metadynamics a history dependent potential that guides the evolution of the system is constructed
as a sum of Gaussian functions centered on the value of each collective variable along the simulation.
Here, a new Gaussian term was added to the historic dependent potential every 1 ps. The metady-
namics parameters of this bias potential were set up as in our previous work [228, 227, 255] (Table
7.2).
Here we have combined metadynamics with its bias exchange variant [34]. Six independent meta-
dynamics simulations were run in parallel. Each replica was biased by diﬀerent one-dimensional
time-dependent potentials, which were built as a function of each of the collective variables deﬁned
above. Exchanges among replicas were attempted every 10 ps using a Metropolis acceptance criterion
[34]. Similar set-ups have shown to improve the sampling of the conﬁgurational space and the con-
vergence of the results [34, 251]. The diﬀerent simulation replicas of the system were run for 30 ns
each (total sampling time of 180 ns). Along these simulations the ligand gets reversibly bound and
unbound to diﬀerent parts of the protein surface. As in standard metadynamics, the replicas were
allowed to run until the diﬀerent bias potentials were converged. To ensure the convergence of the
bias potentials, two average proﬁles were computed: one between times 15 ns and 22.5 ns and the
other between times 22.5 ns and 30 ns. Only portions of the two average proﬁles that agreed with
each other within 1.5 kBT were used for further analysis. (Figure 7.7). An analysis of the converged
bias potentials allows quantifying the relative free energy among all diﬀerent bound states detected
during the simulation.
Laio and collaborators have recently introduced a methodology to reconstruct, from a bias ex-
change metadynamics simulation, the multidimensional free energy landscape from the corresponding
lower dimensional projections [F. Mareinelli, F. Pietrucci, A. Laio and S. Piana, submitted to PLOS
Comp Biol, 2008 ]. This methodology is based on the weighted histogram analysis method (WHAM)
introduced by Kumar et al. [252]. Brieﬂy, the method is based on 1) clustering the phase space
collective variable width of the Gaussian height of the gaussian
distance 0.02 - 0.04 nm 0.05 - 0.14 kcal·mol−1
polar contacts A 0.1 - 0.2 0.05 - 0.14 kcal·mol−1
polar contacts B 0.2 - 0.3 0.05 - 0.14 kcal·mol−1
water bridges 0.8 - 1.0 0.05 - 0.14 kcal·mol−1
RMSD system 0.01 - 0.02 nm 0.05 - 0.14 kcal·mol−1
RMSD binding site 0.01 - 0.02 nm 0.05 - 0.14 kcal·mol−1
Table 7.2: Parameters of the biasing potential in the metadynamics calculations.
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Figure 7.7: Free energy proﬁles at the end of the simulation of 10 protomer as a function of each
collective variable.
explored during the simulations as a function of the collective variables, 2) evaluating the population
of each cluster along each biased trajectory, 3) assigning the unbiased free energy to each cluster
by means of WHAM, using the information from the converged free energy proﬁles. Between 15 ns
and 30 ns, the trajectories of the diﬀerent replicas were evolving under the action of converged bias
potentials (Figure 7.7). Thus, only this part of the simulation data was used for extracting statistical
information.
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